TP53 Gene

Aliases
for TP53 gene

Previous GC identifers: GC17P008026 GC17M008311 GC17M007514 GC17M007772 GC17M007512 GC17M007465

Summaries
for TP53 gene

Genomic Views
for TP53 gene

RefSeq DNA sequence:

NC_000017.10  NC_018928.1  NT_010718.16  

SwitchGear Promoter luciferase reporter plasmids (see all 4): TP53 promoter sequence

QIAGEN PyroMark CpG Assay predesigned Pyrosequencing DNA Methylation assays in human, mouse, rat TP53

TP53 Gene in genomic location: bands according to Ensembl, locations according to (and/or Entrez Gene and/or Ensembl if different)


GeneLoc information about chromosome 17         GeneLoc Exon Structure

GeneLoc location for GC17M007565:  view genomic region     (about GC identifiers)

Proteins
for TP53 gene

6/102 PDB 3D structures from and Proteopedia for TP53 (see all 102):

1A1U (3D)        1AIE (3D)        1C26 (3D)        1DT7 (3D)        1GZH (3D)        1H26 (3D)    

Explore the universe of human proteins at neXtProt for TP53: NX_P04637

Post-translational modifications:

	EMD Millipore Purified and/or Recombinant TP53 Protein
	R&D Systems Recombinant & Natural Proteins for TP53 (p53)
	Enzo Life Sciences proteins for TP53
	OriGene Purified Proteins (see all 3): TP53 OriGene Protein Over-expression Lysate (see all 4): TP53 OriGene Custom Protein Services for TP53
	GenScript Custom Purified and Recombinant Proteins Services for TP53
	Novus Biologicals TP53 Proteins Novus Biologicals TP53 Lysates
	Browse Sino Biological Recombinant Proteins
	ProSpec Recombinant Protein for TP53
	Uscn Proteins for TP53

Gene Ontology (GO): 5/18 cellular component terms (GO ID links to tree view) (see all 18):    About this table

	EMD Millipore Mono- and Polyclonal Antibodies for the study of TP53
	R&D Systems Antibodies for TP53 (p53)
	Cell Signaling Technology (CST) Antibodies for TP53  (p53)
	OriGene Antibodies (see all 21): TP53 OriGene Custom Antibody Services for TP53
	GenScript Superior Antibodies for TP53
	Novus Biologicals TP53 Antibodies
	Abcam antibodies for TP53
	Uscn Antibodies for TP53
	ThermoFisher Antibody for TP53

	EMD Millipore Kits and Assays for the Analysis of TP53
	OriGene Custom Immunoassay Development Browse OriGene Fluorogenic Cell Assay Kits
	R&D Systems ELISAs for TP53 (p53)         (see all)
	GenScript Custom Assay Services for TP53
	Cell Signaling Technology (CST) Sandwich ELISA Kits for TP53 (p53)
	Enzo Life Sciences assays for TP53
	Uscn ELISAs and CLIAs for TP53

Protein Domains /
Families
for TP53 gene

ProtoNet protein and cluster: P04637

Function
for TP53 gene

		10/1931 SABiosciences Target genes for TP53 (see all 1931):
		AATF ABCC3 ABCC6P2 ABCD1 ABCF1 ABHD12 ABHD15 ABHD4 ABHD8 ABTB2

miRNA Products:		miRTarBase miRNAs that target TP53: hsa-mir-1285 (MIRT005474), hsa-mir-16 (MIRT005764), hsa-mir-125a-5p (MIRT004071), hsa-mir-25 (MIRT005417), hsa-mir-221 (MIRT005785), hsa-mir-15a (MIRT005763), hsa-mir-612 (MIRT005476), hsa-mir-222 (MIRT005786), hsa-mir-125b (MIRT000535), hsa-mir-30d (MIRT005418)
		OriGene 3'-UTR Clone (see all 7): TP53 Browse MicroRNA Expression Plasmids
		QIAGEN Custom miScript Target Protector blocks miRNA-binding site of human, mouse, rat TP53
		8/17 QIAGEN miScript miRNA Assays for microRNAs that regulate TP53 (see all 17):
		hsa-miR-576-3p hsa-let-7d hsa-miR-202 hsa-let-7c hsa-let-7g hsa-let-7a hsa-miR-98 hsa-miR-22
		SwitchGear 3'UTR luciferase reporter plasmid: TP53 3' UTR sequence

Inhib. RNA Products:		Browse for Gene Knock-down Tools from EMD Millipore
		OriGene 29mer shRNA kits in GFP-retroviral vector in human, mouse, rat for TP53 (see all 4) OriGene shRNA RFP: TP53 OriGene siRNA: TP53
		QIAGEN FlexiTube/FlexiPlate siRNA for gene silencing in human, mouse, rat TP53

Gene Editing Products:

DNA2.0 Custom Protein Engineering Service for TP53

Clone Products:		Browse Clones for the Expression of Recombinant Proteins Available from EMD Millipore
		OriGene Myc/DDK tagged cDNA clones in CMV expression vector in human, mouse, rat for TP53 (see all 9) OriGene untagged cDNA clones in CMV expression vector in human, mouse, rat for TP53 (see all 7) OriGene custom cloning services – gene synthesis, subcloning, mutagenesis, variant library, vector shuttling
		GenScript: all cDNA clones in your preferred vector (see all 7): TP53 (NM_000546)
		Sino Biological Human cDNA Clone for TP53
		DNA2.0 Custom Codon Optimized Gene Synthesis Service for TP53
		Vector BioLabs ready-to-use adenovirus/AAV for human, mouse, rat TP53

Cell Line Products:		GenScript Custom overexpressing Cell Line Services for TP53
		Search LifeMap BioReagents cell lines for TP53

In Situ Assay Products:

Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for TP53

Gene Ontology (GO): 5/30 molecular function terms (GO ID links to tree view) (see all 30):    About this table

15/27 MGI mutant phenotypes (inferred from 64 alleles) (MGI details for Trp53)

Pathways & Interactions
for TP53 gene

	Super-pathway	contained gene-specific pathways
1	Ubiquitinated Orc1 is degraded by the proteasome	Autodegradation of the E3 ubiquitin ligase COP1 0.92 p53-Dependent G1 DNA Damage Response 0.83 Stabilization of p53 0.91 G1/S DNA Damage Checkpoints 0.79 p53-Dependent G1/S DNA damage checkpoint 0.83 Cell Cycle Checkpoints 0.42
2	Apoptotic Pathways in Synovial Fibroblasts	Apoptotic Pathways in Synovial Fibroblasts 1.00 Telomerase Components in Cell Signaling 0.72 p53 Mediated Apoptosis 0.84 Cellular Apoptosis Pathway 0.65 Mitochondrial Apoptosis 0.73
3	Glioma	Glioma 1.00 Prostate cancer 0.39 Non-small cell lung cancer 0.53 Signaling Pathways in Glioblastoma 0.36 Melanoma 0.43
4	Development HGF signaling pathway	Development_Neurotrophin family signaling 0.45 Apoptosis and survival Role of CDK5 in neuronal death and survival 0.24 Development Neurotrophin family signaling 0.45 Neurotrophin signaling pathway 0.20 Apoptosis and survival_Role of CDK5 in neuronal death and survival 0.24
5	Endometrial cancer	Endometrial cancer 1.00 Signal transduction PTEN pathway 0.45 Signal transduction_PTEN pathway 0.45 Colorectal cancer 0.42

5/16 EMD Millipore Pathways for TP53

	DNA damage ATM/ATR regulation of G1/S checkpoint
	Proteolysis Putative SUMO-1 pathway
	Immune response MIF in innate immunity response
	DNA damage DNA-damage-induced responses
	DNA damage Role of SUMO in p53 regulation

1 R&D Systems Pathway for TP53

Apoptosis Signaling Pathways

5/41 Downloadable PowerPoint Slides of QIAGEN Pathway Central Maps for TP53

	Telomerase Components in Cell Signaling
	UVB-Induced MAPK Signaling
	Mitochondrial Apoptosis
	Molecular Mechanisms of Cancer
	TRKA Signaling

2 Cell Signaling Technology (CST) Pathways for TP53

	Cell Cycle / Checkpoint Control
	DNA Damage

4 Tocris Bioscience Pathways for TP53

	Akt Pathway
	Apoptosis Pathway
	MAPK Pathway
	mTOR Pathway

5/13 GeneGo (Thomson Reuters) Pathways for TP53

	DNA damage ATM/ATR regulation of G1/S checkpoint
	Immune response MIF in innate immunity response
	Transcription P53 signaling pathway
	Development Neurotrophin family signaling
	Signal transduction AKT signaling

5/34 BioSystems Pathways for TP53

	Signaling Pathways in Glioblastoma
	Fluoropyrimidine Activity
	Cell cycle
	Senescence and Autophagy
	AMPK signaling

5/9        Reactome Pathways for TP53

	Hemostasis
	Stabilization of p53
	Cell Cycle
	G1/S DNA Damage Checkpoints
	p53-Dependent G1 DNA Damage Response

2 PharmGKB Pathways for TP53

	Doxorubicin Pathway (Cancer Cell), Pharmacodynamics
	Fluoropyrimidine Pathway, Pharmacodynamics

5/23         Kegg Pathways  (Kegg details for TP53)

	MAPK signaling pathway
	Cell cycle
	p53 signaling pathway
	Apoptosis
	Wnt signaling pathway

Gene Ontology (GO): 5/92 biological process terms (GO ID links to tree view) (see all 92):    About this table

Drugs & Compounds
for TP53 gene

Transcripts
for TP53 gene

Expression
for TP53 gene

TP53 expression in normal human tissues (normalized intensities)
See probesets specificity/sensitivity at GeneAnnot
About this imageBioGPS
CGAP TAG: GAGGAGCCGC

1 LifeMap In Vivo Development Anatomical Compartment/Cell
	Tissue Anatomical Compartment Cell			Category (developmental path)
	Neural CrestCranial Neural CrestCranial Neural Crest Cells			Neural Crest
Expression: Positive    Negative     Selective marker Experimental details: Curated     Microarrays     In-situ hybridization
Stem Cell Differentiation: 1 LifeMap Cell
	Name			Category
	Induced pluripotent stem cell line 20D17 (Induced Pluripotent Stem Cell)			Early Embryo, Fibroblast

Primer Products:		OriGene genome-wide validated SYBR primer pairs in human, mouse, rat for TP53 Browse OriGene validated miRNA SYBR primer pairs
		SABiosciences RT2 qPCR Primer Assay in human, mouse, rat TP53
		QIAGEN QuantiTect SYBR Green Assays in human, mouse, rat TP53
		Search QIAGEN QuantiFast Probe-based Assays in human, mouse, rat TP53

In Situ Assay Products:

Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for TP53

Orthologs
for TP53 gene

Paralogs
for TP53 gene

Paralogs for TP53 gene

TP73²  TP63²  

3 SIMAP similar genes for TP53 using alignment to 88 protein entries:     P53_HUMAN (see all proteins):

p53    TP73    TP63

TP53 for paralogs           About GeneDecksing

Genomic Variants
for TP53 gene

10/603 NCBI SNPs in TP53 are shown (see all 603)     About this table

Genomic Data					Transcription Related Data				Allele Frequencies
SNP ID	Valid	Clinical significance	Chr 17 pos	Sequence	#	AA Chg	Type	More	#	Allele freq	Pop	Total sample	More
-1st2nd3rd	-1st2nd3rd	-1st2nd3rd	-1st2nd3rd	--	--	--	-1st2nd3rd	--	--	-1st2nd3rd	-1st2nd3rd	-1st2nd3rd
rs10425221,2	C,F,A,H,	non-pathogenic	7579472(-)	TCCCCG/CCGTGG	13	/P /R	us2k1 mis1		35		MN NS EA NA WA EU	7378
rs1219126671,2	C	pathogenic	7577084(-)	CACAGA/TGGAAG	16	E V	mis1		0	--	--	--	--
rs289345741,2	C	pathogenic	7577094(-)	GAGACC/TGGCGC	16	R W	mis1 ese3		2		NA	4
rs289345761,2	C,	pathogenic	7577120(-)	GGTGCG/ATGTTT	16	/H /R	mis1 ese3		2		NA	4
rs289345771,2	C	pathogenic	7577511(-)	CACACT/AGGAAG	16	/Q /L	mis1 ese3		2		NA	4
rs115406521,2	C	pathogenic	7577538(-)	GAACCG/AGAGGC	16	/Q /R	mis1 ese3		6		NS EA NA	406
rs1219126511,2	C	pathogenic	7577539(-)	TGAACC/TGGAGG	16	R W	mis1		0	--	--	--	--
rs289345731,2	C	pathogenic	7577559(-)	CAGTTC/TCTGCA	16	S F	mis1 ese3		2		NA	4
rs289345781,2	C	pathogenic	7578406(-)	GAGGCG/ACTGCC	16	/H /R	mis1		2		NA	4
rs289348731,2	C	pathogenic	7578532(-)	CAAGAT/CGTTTT	16	/T /M	mis1		1		NA	2

HapMap Linkage Disequilibrium report for TP53 (7565097 - 7590863 bp)
Structural Variations (Copy Number Variations, Insertions/Deletions, Inversions)
      Database of Genomic Variants (DGV) variations for TP53: --
Human Gene Mutation Database (HGMD): TP53

Locus Specific Mutation Databases (LSDB): TP53

5/120 SABiosciences Cancer Mutation PCR Assays for TP53 (see all 120): Cosmic Id AA Change 10812 p.S241F 10856 p.E294* 11089 p.I195T 10889 p.H179R 43559 p.V173L

5/22 SABiosciences Cancer Mutation PCR Arrays containing TP53 (see all 22): Breast Cancer Cancer Comprehensive Panel 384HT Lung Cancer Myelodysplastic Syndromes Soft Tissue Tumors

2 SABiosciences qBiomarker Copy Number PCR Arrays containing TP53: Oncogenes & Tumor Suppressor Genes 384HC WNT Signaling

QIAGEN SeqTarget long-range PCR primers in human, mouse, rat for resequencing TP53

DNA2.0 Custom Variant and Variant Library Synthesis for TP53

Disorders / Diseases
for TP53 gene

20/594 diseases for TP53

10/96 Novoseek disease relationships for TP53 gene (see all 96)    About this table

Publications
for TP53 gene

PubMed articles for TP53 gene, integrated from 9 sources (see all 14923) (see top 10): (articles sorted by number of sources associating them with TP53)

Utopia: connect your pdf to the dynamic world of online information

1. Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. (PubMed id 6396087)^{1, 2, 3} Matlashewski G....Benchimol S. (1984)
2. TP53 mutations in breast cancer tumors of patients from Rio de Janeiro, Brazil: association with risk factors and tumor characteristics. (PubMed id 12209590)^{1, 4, 9} Simao T.A....de Moura-Gallo C.V. (2002)
3. Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family. (PubMed id 10484981)^{1, 2, 9} Gueran S.... Imirzalioglu N. (1999)
4. Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. (PubMed id 19536131)^{1, 2, 9} Lee E.-W.... Song J. (2009)
5. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. (PubMed id 8875929)^{1, 2, 9} Kussie P.H.... Pavletich N.P. (1996)
6. Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. (PubMed id 16314399)^{1, 4, 9} Ma H....Shen H. (2006)
7. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. (PubMed id 16203772)^{1, 4, 9} Sotamaa K....de la Chapelle A. (2005)
8. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. (PubMed id 12802680)^{1, 4, 9} Hwang S.J....Strong L.C. (2003)
9. [p53 gene polymorphism with susceptibility to esophageal cancer and lung cancer in Chinese population] (PubMed id 12921568)^{1, 4, 9} Zhang J.H....He M. (2003)
10. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. (PubMed id 16287156)^{1, 4, 9} Zhang X....Lin D. (2006)
11. Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. (PubMed id 16289646)^{1, 4, 9} Lai K.C....Tsai F.J. (2005)
12. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women. (PubMed id 16054204)^{1, 4, 9} Bhattacharya P. and Sengupta S. (2005)
13. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. (PubMed id 16110022)^{1, 4, 9} Westra J.L....Plukker J.T. (2005)
14. [Population genetic analysis of the association between the BRCA1 and P53 gene polymorphisms and the risk of sporadic breast cancer] (PubMed id 16161633)^{1, 4, 9} Tarasov V.A....Mel'nik V.A. (2005)
15. Gene-gene and gene-environmental interactions of p53, p21, and IRF-1 polymorphisms in Korean women with cervix cancer. (PubMed id 14764039)^{1, 4, 9} Lee J.E....Park J.S. (2004)
16. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. (PubMed id 12824702)^{1, 4, 9} Suzuki K....Yamanaka H. (2003)
17. The p53 codon 72 polymorphism and risk of oral cancer in Southern Thailand. (PubMed id 14507241)^{1, 4, 9} Kietthubthew S....Ishida T. (2003)
18. Investigation of bax, bcl-2, bcl-x and p53 gene polymorphisms in multiple sclerosis. (PubMed id 12161031)^{1, 4, 9} Kuhlmann T....Bruck W. (2002)
19. BRAF mutation in endometrial carcinoma and hyperplasi a: correlation with KRAS and p53 mutations and mismatch repair protein expressi on. (PubMed id 16144912)^{1, 4, 9} Feng Y.Z....Konishi I. (2005)
20. Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma. (PubMed id 15023836)^{1, 4, 9} Ronchetti D....Pignataro L. (2004)
21. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. (PubMed id 15598783)^{1, 4, 9} Huang S.P....Huang C.H. (2004)
22. [p53 gene codon 72 polymorphism and susceptibility to esophageal squamous cell carcinoma in a Chinese population] (PubMed id 11836677)^{1, 4, 9} Zhang L....Lin D. (2002)
23. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. (PubMed id 11504770)^{1, 4, 9} Smith J.S....Jenkins R.B. (2001)
24. Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. (PubMed id 11447225)^{1, 2, 9} Xie S....Dai W. (2001)
25. The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. (PubMed id 10884347)^{1, 2, 9} Luciani M.G....Hupp T.R. (2000)
26. Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. (PubMed id 8829627)^{1, 2, 9} Audrezet M.-P.... Ferec C. (1996)
27. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. (PubMed id 1349102)^{1, 4, 9} Crook T....Vousden K.H. (1992)
28. p53 mutations in colorectal cancer. (PubMed id 1699228)^{1, 2, 9} Rodrigues N.R.... Lane D.P. (1990)
29. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. (PubMed id 16364249)^{1, 4, 9} Santos A.M....Medeiros R. (2006)
30. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. (PubMed id 15240512)^{1, 4, 9} Xi Y.G....Ke Y. (2004)
31. [Correlation between P53 codon 72 polymorphism and tumorigenesis of cervical cancer] (PubMed id 15566643)^{1, 4, 9} Li C.Y....Huang B.J. (2004)
32. A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism. (PubMed id 15104366)^{1, 4, 9} Zhang Z.W....Holly J. (2004)
33. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. (PubMed id 14660794)^{1, 2, 9} Kanashiro C.A....Varga J.L. (2003)
34. Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. (PubMed id 12907646)^{1, 4, 9} Leslie A....Steele R.J. (2003)
35. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. (PubMed id 12810724)^{1, 2, 9} Louria-Hayon I....Haupt Y. (2003)
36. [Study on the relationship between cervical cancer and p53 codon 72 polymorphism] (PubMed id 12575207)^{1, 4, 9} Qie M....Wu J. (2002)
37. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. (PubMed id 8118819)^{1, 2, 9} Birch J.M.... Santibanez-Koref M.F. (1994)
38. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. (PubMed id 7682763)^{1, 2, 9} Caamano J.... Klein-Szanto A.J.P. (1993)
39. A germ line mutation in exon 5 of the p53 gene in an extended cancer family. (PubMed id 1933902)^{1, 2, 9} Law J.C.... Ferrell R.E. (1991)
40. Mutations of the P53 gene, including an intronic point mutation, in colorectal tumors. (PubMed id 1647768)^{1, 2, 9} Ishioka C.... Yamazaki T. (1991)
41. BRD7 is a candidate tumour suppressor gene required f or p53 function. (PubMed id 20228809)^{1, 2, 9} Drost J....Del Sal G. (2010)
42. [Application of oligonucleotide microarray primer extension to detection of p53 single nucleotide polymorphisms] (PubMed id 16004824)^{1, 4, 9} Wu Q.H....Zheng W.L. (2005)
43. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. (PubMed id 16061860)^{1, 4, 9} Hernandez S....Real F.X. (2005)
44. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. (PubMed id 16030116)^{1, 4, 9} Wiencke J.K....Wrensch M. (2005)
45. The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms. (PubMed id 15534883)^{1, 4, 9} Liu G....Christiani D.C. (2004)
46. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. (PubMed id 15099969)^{1, 4, 9} Roh J.W....Lee H.P. (2004)
47. Spectrum of p53 tumor suppressor gene mutations and breast cancer survival. (PubMed id 14997055)^{1, 4, 9} Lai H....Lai S. (2004)
48. [Functional polymorphism of p53 and CCR5 genes in the long-lived of the Siberian region] (PubMed id 15651660)^{1, 4, 9} Smetannikova M.A....Voevoda M.I. (2004)
49. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. (PubMed id 15186775)^{1, 2, 9} An W.... Roeder R.G. (2004)
50. [Correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance] (PubMed id 16200870)^{1, 4, 9} Zhou C.Z....Xu J. (2004)
51. [Association of p53 gene polymorphism with susceptibility to ovarian cancer] (PubMed id 15634502)^{1, 4, 9} Kang S....Li Y. (2004)
52. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. (PubMed id 12724314)^{1, 2, 9} Wang Y.H.... Lee S.C. (2003)
53. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. (PubMed id 11780126)^{1, 2, 9} D'Orazi G.... Soddu S. (2002)
54. Regulation of p53 activity by its interaction with homeodomain- interacting protein kinase-2. (PubMed id 11740489)^{1, 2, 9} Hofmann T.G.... Schmitz M.L. (2002)
55. Waf-1 (p21) and p53 polymorphisms in breast cancer. (PubMed id 11815410)^{1, 4, 9} Keshava C....Weston A. (2002)
56. p53 amino acids 339-346 represent the minimal p53 repression domain. (PubMed id 11007800)^{1, 2, 9} Hong T.M.... Wu C.W. (2001)
57. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. (PubMed id 11481490)^{1, 2, 9} Ribeiro R.C.... Sandrini R. (2001)
58. Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8. (PubMed id 11023613)^{1, 2, 9} Anderson C.W. and Allalunis-Turner M.J. (2000)
59. Drastic genetic instability of tumors and normal tissues in Turcot syndrome. (PubMed id 9419979)^{1, 2, 9} Miyaki M.... Utsunomiya J. (1997)
60. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. (PubMed id 7887414)^{1, 2, 9} Frebourg T.... Friend S.H. (1995)
61. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. (PubMed id 7878469)^{1, 2, 9} Jeffrey P.D.... Pavletich N.P. (1995)
62. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. (PubMed id 8336944)^{1, 2, 9} Hamelin R.... Thomas G. (1993)
63. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. (PubMed id 1327751)^{1, 2, 9} Crook T. and Vousden K.H. (1992)
64. Frequent p53 mutations in head and neck cancer. (PubMed id 1394225)^{1, 2, 9} Somers K.D....Casey G. (1992)
65. Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. (PubMed id 1737852)^{1, 2, 9} Felix C.A.... Minna J.D. (1992)
66. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. (PubMed id 1999338)^{1, 2, 9} Olschwang S.... Thomas G. (1991)
67. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. (PubMed id 1849234)^{1, 2, 9} Hsu I.C.... Harris C.C. (1991)
68. Frequent mutation of the p53 gene in human esophageal cancer. (PubMed id 2263646)^{1, 2, 9} Hollstein M.C.... Harris C.C. (1990)
69. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. (PubMed id 2259385)^{1, 2, 9} Srivastava S.... Chang E.H. (1990)
70. p53 opens the mitochondrial permeability transition po re to trigger necrosis. (PubMed id 22726440)^{1, 2} Vaseva A.V....Moll U.M. (2012)
71. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. (PubMed id 22864287)^{1, 2} Cui G.... Mer G. (2012)
72. Aurora B interacts with NIR-p53, leading to p53 phosp horylation in its DNA-binding domain and subsequent functional suppression. (PubMed id 20959462)^{1, 2} Wu L....Jain A. (2011)
73. NIRF constitutes a nodal point in the cell cycle netw ork and is a candidate tumor suppressor. (PubMed id 21952639)^{1, 2} Mori T....Kochi H. (2011)
74. A large intergenic noncoding RNA induced by p53 media tes global gene repression in the p53 response. (PubMed id 20673990)^{1, 2} Huarte M....Rinn J.L. (2010)
75. USP10 regulates p53 localization and stability by deubiquitinating p53. (PubMed id 20096447)^{1, 2} Yuan J.... Lou Z. (2010)
76. Polybromo-associated BRG1-associated factor component s BRD7 and BAF180 are critical regulators of p53 required for induction of repl icative senescence. (PubMed id 20660729)^{1, 2} Burrows A.E....Elledge S.J. (2010)
77. RFWD3-Mdm2 ubiquitin ligase complex positively regula tes p53 stability in response to DNA damage. (PubMed id 20173098)^{1, 2} Fu X....Wang Y. (2010)
78. G-protein-coupled receptor kinase 5 phosphorylates p5 3 and inhibits DNA damage-induced apoptosis. (PubMed id 20124405)^{1, 2} Chen X....Ma L. (2010)
79. Diversity in DNA recognition by p53 revealed by cryst al structures with Hoogsteen base pairs. (PubMed id 20364130)^{1, 2} Kitayner M....Shakked Z. (2010)
80. G9a and Glp methylate lysine 373 in the tumor suppres sor p53. (PubMed id 20118233)^{1, 2} Huang J....Berger S.L. (2010)
81. The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. (PubMed id 20870725)^{1, 2} West L.E.... Gozani O. (2010)
82. Pyk2 inhibition of p53 as an adaptive and intrinsic m echanism facilitating cell proliferation and survival. (PubMed id 19880522)^{1, 2} Lim S.T....Schlaepfer D.D. (2010)
83. JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation. (PubMed id 19509332)^{1, 2} Sun L.... Shang Y. (2009)
84. Trim24 targets endogenous p53 for degradation. (PubMed id 19556538)^{1, 2} Allton K....Barton M.C. (2009)
85. Human cytomegalovirus IE1-72 protein interacts with p 53 and inhibits p53-dependent transactivation by a mechanism different from tha t of IE2-86 protein. (PubMed id 19776115)^{1, 2} Hwang E.S....Huang E.S. (2009)
86. Plk1-mediated phosphorylation of Topors regulates p53 stability. (PubMed id 19473992)^{1, 2} Yang X....Liu X. (2009)
87. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. (PubMed id 18996393)^{1, 2} Suad O....Shakked Z. (2009)
88. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. (PubMed id 18650397)^{1, 2} Boeckler F.M....Fersht A.R. (2008)
89. Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. (PubMed id 17967874)^{1, 2} Shouse G.P....Liu X. (2008)
90. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. (PubMed id 18206965)^{1, 2} Lim S.T....Ilic D. (2008)
91. Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution. (PubMed id 18453682)^{1, 2} Tu C....Ji X. (2008)
92. PRAK is essential for ras-induced senescence and tumor suppression. (PubMed id 17254968)^{1, 2} Sun P....Han J. (2007)
93. Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. (PubMed id 17591690)^{1, 2} Lee J.H....Kim K.T. (2007)
94. A specific PP2A regulatory subunit, B56gamma, mediates DNA damage- induced dephosphorylation of p53 at Thr55. (PubMed id 17245430)^{1, 2} Li H.H.... Liu X. (2007)
95. p53 is regulated by the lysine demethylase LSD1. (PubMed id 17805299)^{1, 2} Huang J.... Berger S.L. (2007)
96. Modulation of p53 function by SET8-mediated methylation at lysine 382. (PubMed id 17707234)^{1, 2} Shi X....Gozani O. (2007)
97. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. (PubMed id 17170702)^{1, 2} Yamasaki S.... Nakajima T. (2007)
98. The notch regulator MAML1 interacts with p53 and functions as a coactivator. (PubMed id 17317671)^{1, 2} Zhao Y.... Band V. (2007)
99. Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9. (PubMed id 18022393)^{1, 2} Arai S.... Kurokawa R. (2007)
100. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. (PubMed id 17349958)^{1, 2} Taira N.... Yoshida K. (2007)
101. LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. (PubMed id 17108107)^{1, 2} Zeng P.Y. and Berger S.L. (2006)
102. Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. (PubMed id 16377624)^{1, 2} Yoshida K....Miki Y. (2006)
103. Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. (PubMed id 16402859)^{1, 2} Hu M.... Shi Y. (2006)
104. Repression of p53 activity by Smyd2-mediated methylation. (PubMed id 17108971)^{1, 2} Huang J.... Berger S.L. (2006)
105. Structural basis for the methylation site specificity of SET7/9. (PubMed id 16415881)^{1, 2} Couture J.-F.... Trievel R.C. (2006)
106. The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. (PubMed id 16704422)^{1, 2} Blanco S....Lazo P.A. (2006)
107. Molecular recognition of p53 and MDM2 by USP7/HAUSP. (PubMed id 16474402)^{1, 2} Sheng Y....Frappier L. (2006)
108. Protein kinase A phosphorylates and regulates dimerization of 14-3-3 epsilon. (PubMed id 16376338)^{1, 2} Gu Y.-M.... Lee K.-Y. (2006)
109. Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. (PubMed id 16353134)^{1, 4} Talseth B.A....Scott R.J. (2006)
110. Critical role for Daxx in regulating Mdm2. (PubMed id 16845383)^{1, 2} Tang J....Yang X. (2006)
111. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. (PubMed id 16258005)^{1, 4} Bougeard G....Frebourg T. (2006)
112. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. (PubMed id 16331344)^{1, 4} Tan X.L....Chang-Claude J. (2006)
113. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. (PubMed id 15979781)^{1, 4} Zhu Z.Z....Zhu G.S. (2005)
114. Effects of dietary intake and genetic factors on hypermethylation of the hMLH1 gene promoter in gastric cancer. (PubMed id 15991278)^{1, 4} Nan H.M....Kim H. (2005)
115. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. (PubMed id 16230424)^{1, 4} Hong Y....Lin D. (2005)
116. Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15. (PubMed id 15960923)^{1, 4} Soto Martinez J.L....Lopez-Nevot M.A. (2005)
117. NIR is a novel INHAT repressor that modulates the transcriptional activity of p53. (PubMed id 16322561)^{1, 2} Hublitz P....Schule R. (2005)
118. p53 isoforms can regulate p53 transcriptional activity. (PubMed id 16131611)^{1, 2} Bourdon J.C.... Lane D.P. (2005)
119. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. (PubMed id 15837541)^{1, 4} Kalemi T.G....Kotsis A. (2005)
120. Genetic variants of TP53 and EPHX1 in Leber's hereditary optic neuropathy and their relationship to age at onset. (PubMed id 15838728)^{1, 4} Ishikawa K....Mashima Y. (2005)
121. Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. (PubMed id 15855171)^{1, 2} Golubovskaya V.M....Cance W.G. (2005)
122. Polymorphism of the p53 tumor suppressor gene is associated with susceptibility to uterine leiomyoma. (PubMed id 16009172)^{1, 4} Denschlag D....Pietrowski D. (2005)
123. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. (PubMed id 16077965)^{1, 4} Catalano T....Battista P. (2005)
124. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. (PubMed id 16014569)^{1, 4} Austen B....Stankovic T. (2005)
125. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. (PubMed id 15609317)^{1, 4} Sakiyama T....Yokota J. (2005)
126. TP53-binding protein variants and breast cancer risk: a case-control study. (PubMed id 15987456)^{1, 4} Frank B....Burwinkel B. (2005)
127. Candidate genes associated with ageing and life expectancy in the Jerusalem longitudinal study. (PubMed id 15621215)^{1, 4} Stessman J....Ebstein R.P. (2005)
128. Genotype phenotype correlations in Israeli colorectal cancer patients. (PubMed id 15523694)^{1, 4} Starinsky S....Friedman E. (2005)
129. [p53 gene intron 7 polymorphism and its association with oral neoplasms] (PubMed id 16255923)^{1, 4} Li Y.Q....Wu T.S. (2005)
130. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33- phosphorylated form binds and stabilizes serine 46-phosphorylated p53. (PubMed id 16219768)^{1, 2} Chang N.-S.... Hong Q. (2005)
131. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. (PubMed id 15958551)^{1, 4} Le Calvez F....Hainaut P. (2005)
132. [p53 gene codon 72 polymorphism and susceptibility to keloid] (PubMed id 16128105)^{1, 4} Zhuo Y....Zhao Y.Z. (2005)
133. [Association of p53 codon 72 polymorphism with genetic susceptibility to hepatocellular carcinoma in Chinese population] (PubMed id 16331559)^{1, 4} Zhu Z.Z....Wu M.C. (2005)
134. [Investigation of p53 polymorphism for genetic predisposition of keloid and hypertrophic scar] (PubMed id 15844595)^{1, 4} Wang C.M....Nakazawa N. (2005)
135. Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif. (PubMed id 15701641)^{1, 2} Jalota-Badhwar A....Chattopadhyay S. (2005)
136. [p53 gene codon 72 polymorphism and susceptibility to keloid in Chinese population] (PubMed id 15704837)^{1, 4} Zhuo Y....Zhao Y. (2005)
137. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. (PubMed id 15723718)^{1, 4} Niwa Y....Hamajima N. (2005)
138. [p53 gene codon 72 polymorphism and genetic susceptibility to hepatocellular carcinoma in Chinese population] (PubMed id 15774209)^{1, 4} Zhu Z.Z....Wu M.C. (2005)
139. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). (PubMed id 15489334)^{1, 2} Gerhard D.S....Malek J. (2004)
140. Regulation of human p53 activity and cell localization by alternative splicing. (PubMed id 15340061)^{1, 2} Ghosh A....Matlashewski G. (2004)
141. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. (PubMed id 14702041)^{1, 2} Katayama H....Sen S. (2004)
142. Regulation of p53 activity through lysine methylation. (PubMed id 15525938)^{1, 2} Chuikov S....Reinberg D. (2004)
143. TP53 haplotype-based analysis and incidence of post-angioplasty restenosis. (PubMed id 14740296)^{1, 4} Zee R.Y....Lindpaintner K. (2004)
144. Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. (PubMed id 15036662)^{1, 4} Wu M.T....Wu D.C. (2004)
145. [Significance of p53 gene mutation and P53 protein expression abnormality on the prognosis of esophageal cancer: a meta-analysis study.] (PubMed id 15555357)^{1, 4} Wang X.L....Xu S.Q. (2004)
146. Polymorphisms of DNA repair genes and risk of glioma. (PubMed id 15313891)^{1, 4} Wang L.E....Wei Q. (2004)
147. Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. (PubMed id 15291355)^{1, 4} Hishida A....Hamajima N. (2004)
148. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. (PubMed id 14534297)^{1, 2} Joerger A.C....Fersht A.R. (2004)
149. Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. (PubMed id 15053879)^{1, 2} Li H.-H.... Liu X. (2004)
150. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. (PubMed id 15138483)^{1, 4} Menzel H.J....Kraft H.G. (2004)
151. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. (PubMed id 14647431)^{1, 4} Gemignani F....Canzian F. (2004)
152. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. (PubMed id 12851404)^{1, 2} Tomasini R.... Dusetti N.J. (2003)
153. An association study of the codon 72 polymorphism in the pro-apoptotic gene p53 and Alzheimer's disease. (PubMed id 12648751)^{1, 4} Rosenmann H....Abramsky O. (2003)
154. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. (PubMed id 12750254)^{1, 2} Shiseki M....Harris C.C. (2003)
155. Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations. (PubMed id 12917199)^{1, 4} Medina P.P....Sanchez-Cespedes M. (2003)
156. The p53 codon 72 genotypes in HPV infection and cervical disease. (PubMed id 12818446)^{1, 4} Abba M.C....Golijow C.D. (2003)
157. Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypes. (PubMed id 12875622)^{1, 4} Hiraki A....Tajima K. (2003)
158. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (review). (PubMed id 12883749)^{1, 4} Xing D....Lin D. (2003)
159. Analysis of polymorphic patterns in candidate genes in Israeli patients with prostate cancer. (PubMed id 14719475)^{1, 4} Figer A....Friedman E. (2003)
160. Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). (PubMed id 12702766)^{1, 2} Kondo S.... Thukral S.K. (2003)
161. [Risk factors for cervico-uterine cancer associated to HPV: p53 codon 72 polymorphism in women attending hospital care] (PubMed id 12708345)^{1, 4} Sifuentes Alvarez A. and Reyes Romero M. (2003)
162. Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. (PubMed id 12944468)^{1, 2} O'Keefe K.... Zhang Y. (2003)
163. [Development of chronic obstructive pulmonary disease correlates with mini- and microsatellite locus instability] (PubMed id 12838617)^{1, 4} Chizhikov V.V....Zborovskaia I.B. (2003)
164. [Association between Bam HI RFLP p53 gene polymorphism and brain infarction volume in patients with atherothrombotic ischemic stroke] (PubMed id 12830514)^{1, 4} Skvortsova V.I....Platonova I.A. (2003)
165. The p53 codon 72 polymorphism in Thai nasopharyngeal carcinoma. (PubMed id 12893432)^{1, 4} Tiwawech D....Ishida T. (2003)
166. Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. (PubMed id 11927843)^{1, 4} Wang-Gohrke S....Chang-Claude J. (2002)
167. Effect of germ-line genetic variation on breast cancer survival in a population-based study. (PubMed id 12036913)^{1, 4} Goode E.L....Pharoah P.P. (2002)
168. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. (PubMed id 12019159)^{1, 4} Miller D.P....Christiani D.C. (2002)
169. [Polymorphism in codon 72 of the p53 gene and cervico-uterine cancer risk in Mexico] (PubMed id 12221910)^{1, 4} Suarez-Rincon A.E....Sanchez-Corona J. (2002)
170. The p53Pro72Arg polymorphism is associated with albuminuria among aboriginal Australians. (PubMed id 11856771)^{1, 4} McDonald S.P....Wang X.L. (2002)
171. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. (PubMed id 11925430)^{1, 2} Kim E.-J.... Um S.-J. (2002)
172. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. (PubMed id 12430182)^{1, 4} Hamajima N....Tajima K. (2002)
173. A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients. (PubMed id 11844595)^{1, 4} Biros E....Stubna J. (2002)
174. Investigations on a clinically and functionally unusual and novel germline p53 mutation. (PubMed id 12085209)^{1, 2} Rutherford J.... Camplejohn R.S. (2002)
175. Multi-locus interactions predict risk for post-PTCA restenosis: an approach to the genetic analysis of common complex disease. (PubMed id 12082592)^{1, 4} Zee R.Y....Lindpainter K. (2002)
176. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. (PubMed id 12507430)^{1, 2} Hu M....Shi Y. (2002)
177. Differential effect of ik3-1/cables on p53- and p73-induced cell death. (PubMed id 11706030)^{1, 2} Tsuji K.... Matsuoka M. (2002)
178. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. (PubMed id 11672523)^{1, 2} Vaziri H.... Weinberg R.A. (2001)
179. Genetic polymorphisms of CYP1A1, GSTM1 and P53 genes in a unique Siberian population of Tundra Nentsi and its pharmacogenetic importance. (PubMed id 11507974)^{1, 4} Duzhak T.G....Lyakhovich V.V. (2001)
180. Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. (PubMed id 11546806)^{1, 2} Abe Y.... Enomoto Y. (2001)
181. A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. (PubMed id 11668523)^{1, 4} Kumar R....Hemminki K. (2001)
182. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. (PubMed id 11239457)^{1, 2} Keller D.M....Lu H. (2001)
183. Zinc binding and redox control of p53 structure and function. (PubMed id 11554448)^{1, 2} Hainaut P. and Mann K. (2001)
184. A unique basal pattern of p53 expression in ulcerative colitis is associated with mutation in the p53 gene. (PubMed id 11737306)^{1, 4} Noffsinger A.E....Fenoglio-Preiser C.M. (2001)
185. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. (PubMed id 11058590)^{1, 2} Chang N.-S....Zevotek N. (2001)
186. Association study of the p53-gene Pro72Arg polymorphism in schizophrenia. (PubMed id 11814547)^{1, 4} Chiu H.J....Tsai S.J. (2001)
187. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. (PubMed id 11551930)^{1, 2} Xie S....Dai W. (2001)
188. A p53 polymorphism associated with increased risk of hepatitis C virus infection. (PubMed id 11566488)^{1, 4} Okada F....Sato S. (2001)
189. Post-translational modification of p53 protein in response to ionizing radiation analyzed by mass spectrometry. (PubMed id 10656795)^{1, 2} Abraham J.... Benchimol S. (2000)
190. The function of PML in p53-dependent apoptosis. (PubMed id 11025664)^{1, 2} Guo A....Pandolfi P.P. (2000)
191. Immunohistochemical expression of p53 in breast carcinoma is associated with the intron 1 BglII polymorphism of the p53 gene. (PubMed id 11024482)^{1, 4} Trejo-Becerril C....Duenas-Gonzalez A. (2000)
192. The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine- 18 within the mdm-2 binding site of the p53 tumour suppressor protein. (PubMed id 10951572)^{1, 2} Lopez-Borges S. and Lazo P.A. (2000)
193. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. (PubMed id 11097227)^{1, 4} Pierce L.M....Le Marchand L. (2000)
194. p53 is involved in the p120E4F-mediated growth arrest. (PubMed id 10644996)^{1, 2} Sandy P....Del Sal G. (2000)
195. Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. (PubMed id 10606744)^{1, 2} Dumaz N....Meek D.W. (1999)
196. Regulation of CAK kinase activity by p53. (PubMed id 9840937)^{1, 2} Schneider E....Wagner P. (1998)
197. Detection of p53 gene mutations in oral squamous cell carcinomas of a black African population sample. (PubMed id 9450901)^{1, 2} van Rensburg E.J....Raubenheimer E.J. (1998)
198. Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. (PubMed id 9321402)^{1, 2} McCoy M....Halazonetis T.D. (1997)
199. Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. (PubMed id 9101296)^{1, 2} Guldberg P....Zeuthen J. (1997)
200. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. (PubMed id 9372954)^{1, 2} Ko L.J....Pan Z.Q. (1997)
201. Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. (PubMed id 8829653)^{1, 2} de Vries E.M.G.... Sommer S.S. (1996)
202. Regulation of specific DNA binding by p53: evidence for a role for O- glycosylation and charged residues at the carboxy-terminus. (PubMed id 8632915)^{1, 2} Shaw P.... Iggo R. (1996)
203. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. (PubMed id 8875926)^{1, 2} Gorina S. and Pavletich N.P. (1996)
204. The human tumour suppressor gene p53 is alternatively spliced in normal cells. (PubMed id 8632903)^{1, 2} Flaman J.-M.... Frebourg T. (1996)
205. An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. (PubMed id 8825920)^{1, 2} Varley J.M....Evans D.G.R. (1995)
206. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. (PubMed id 8023157)^{1, 2} Cho Y.... Pavletich N.P. (1994)
207. Solution structure of the tetrameric minimum transforming domain of p53. (PubMed id 7773777)^{1, 2} Lee W.... Arrowsmith C.H. (1994)
208. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. (PubMed id 8023159)^{1, 2} Clore G.M.... Gronenborn A.M. (1994)
209. A temperature-sensitive mutant of human p53. (PubMed id 8013454)^{1, 2} Zhang W.... Deisseroth A.B. (1994)
210. p53: at the crossroads of molecular carcinogenesis and risk assessment. (PubMed id 8266092)^{1, 2} Harris C.C. (1993)
211. The incidence of p53 mutations increases with progression of head and neck cancer. (PubMed id 8402617)^{1, 2} Boyle J.O.... Sidransky D. (1993)
212. Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs. (PubMed id 8316628)^{1, 2} Allalunis-Turner M.J....Mirzayans R. (1993)
213. p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. (PubMed id 1437144)^{1, 2} Duthu A.... May P. (1992)
214. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. (PubMed id 1565144)^{1, 2} Malkin D....Strong L.C. (1992)
215. A novel mutation in the p53 gene in a Burkitt's lymphoma cell line. (PubMed id 1303181)^{1, 2} Bhatia K.... Magrath I.T. (1992)
216. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. (PubMed id 1631151)^{1, 2} Sun Y.... Colburn N.H. (1992)
217. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. (PubMed id 1459726)^{1, 2} Sakai E.... Tsuchida N. (1992)
218. The tumor suppressor p53 is bound to RNA by a stable covalent linkage. (PubMed id 1705009)^{1, 2} Samad A. and Carroll R.B. (1991)
219. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. (PubMed id 1672732)^{1, 2} Bressac B.... Ozturk M. (1991)
220. p53 gene mutations in Barrett's epithelium and esophageal cancer. (PubMed id 1868473)^{1, 2} Casson A.G....Roth J.A. (1991)
221. Identification of p53 as a sequence-specific DNA-binding protein. (PubMed id 2047879)^{1, 3} Kern S.E....Vogelstein B. (1991)
222. p53 is frequently mutated in Burkitt's lymphoma cell lines. (PubMed id 1915267)^{1, 2} Farrell P.J.... Crook T. (1991)
223. p53 mutations in human cancers. (PubMed id 1905840)^{1, 2} Hoolstein M.... Harris C.C. (1991)
224. Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen. (PubMed id 1848668)^{1, 2} Scheidtmann K.H.... Walter G. (1991)
225. The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. (PubMed id 2156209)^{1, 2} Addison C.... Sturzbecher H.-W. (1990)
226. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. (PubMed id 1694291)^{1, 2} Bartek J.... Lane D.P. (1990)
227. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. (PubMed id 1978757)^{1, 2} Malkin D....Friend S.H. (1990)
228. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. (PubMed id 2141171)^{1, 2} Bischoff J.R.... Beach D. (1990)
229. A variation in the structure of the protein-coding region of the human p53 gene. (PubMed id 2905688)^{1, 2} Buchman V.L....Georgiev G.P. (1988)
230. Characterization of the human p53 gene. (PubMed id 2946935)^{1, 2} Lamb P. and Crawford L. (1986)
231. Molecular basis for heterogeneity of the human p53 protein. (PubMed id 3025664)^{1, 2} Harris N....Rotter V. (1986)
232. Localization of gene for human p53 tumour antigen to band 17p13. (PubMed id 3456488)^{1, 3} Isobe M....Croce C.M. (1986)
233. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. (PubMed id 4006916)^{1, 2} Zakut-Houri R.... Oren M. (1985)
234. Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. (PubMed id 3894933)^{1, 2} Harlow E.... Adams T.E. (1985)
235. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. (PubMed id 12438652)^{1, 9} Yoon H....Pellegata N.S. (2002)
236. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. (PubMed id 14663467)^{1, 9} Griewe G.L....Srivastava S. (2003)
237. [Expressions of p53 and p21 in nasal NK/T-cell lymphoma and their relationship with the proliferation and apoptosis of cells] (PubMed id 19452712)^{1, 9} Xu G....Chen D. (2009)
238. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes. (PubMed id 19086036)^{1, 9} Yang H....Lu S.C. (2009)
239. High prevalence of p53 exon 4 mutations in soft tissue sarcoma. (PubMed id 17429838)^{1, 9} Das P....Lev D. (2007)
240. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. (PubMed id 11733360)^{1, 9} Quintanilla-Martinez L....Fend F. (2001)
241. MEKK1/JNK signaling stabilizes and activates p53. (PubMed id 9724739)^{1, 9} Fuchs S.Y....Ronai Z. (1998)
242. Potential Increase in the Prognostic Value of p53 Mutation by Pro72 Allele in Stage I Non-Small-Cell Lung Cancer. (PubMed id 19434453)^{1, 9} Chien W.P....Lee H. (2009)
243. Effect of thioredoxin deletion and p53 cysteine repla cement on human p53 activity in wild-type and thioredoxin reductase null yeast. (PubMed id 19681600)^{1, 9} Stoner C.S....Merrill G.F. (2009)
244. Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. (PubMed id 17598983)^{1, 9} Song H. and Xu Y. (2007)
245. Stable formation of mutated p53 multimers in a Chinese hamster cell line causes defective p53 nuclear localization and abrogates its residual function. (PubMed id 16598767)^{1, 9} Ottaggio L....Abbondandolo A. (2006)
246. P53 gene mutation and expression of MDM2, P53, P16 protein and their relationship in human glioma. (PubMed id 16696307)^{1, 9} Cui W....Ren Q. (2005)
247. HIPK2 modulates p53 activity towards pro-apoptotic tr anscription. (PubMed id 19828042)^{1, 9} Puca R....D'Orazi G. (2009)
248. Mutations in p53, p53 protein overexpression and brea st cancer survival. (PubMed id 19602056)^{1, 9} Rossner P....Santella R.M. (2008)
249. Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. (PubMed id 17634554)^{1, 9} Ju J....Chu E. (2007)
250. Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. (PubMed id 15534934)^{1, 9} Pan Z.Z....Huang B.J. (2004)
251. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143. (PubMed id 12670900)^{1, 9} Li Y....Fine R.L. (2003)
252. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. (PubMed id 11313951)^{1, 9} Wu Y....Boxer L.M. (2001)
253. Correlation of p53, MDM2 and p14(ARF) protein express ion in human esophageal squamous cell carcinoma. (PubMed id 19488782)^{1, 9} Cheng T.H....Hsu H.S. (2009)
254. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity. (PubMed id 17150106)^{1, 9} Zhang L....Maki C.G. (2006)
255. Expression of p21(WAF1) and p53 and polymorphism of p21(WAF1) gene in gastric carcinoma. (PubMed id 15069711)^{1, 9} Xie H.L....Li Y.Q. (2004)
256. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. (PubMed id 11978184)^{1, 9} Feng C.W....Xie X.J. (2002)
257. Expression of p53 and bcl-2 proteins in acute leukemias: an immunocytochemical study. (PubMed id 11949843)^{1, 9} Klobusicka M....Babusikova O. (2001)
258. Frequent association of p53 gene mutation in invasive bladder cancer. (PubMed id 1540947)^{4, 9} Fujimoto K....Terada M. (1992)
259. TP53 mutations in endometrial cancers: relation to PT EN gene defects. (PubMed id 20169661)^{1, 9} Janiec-Jankowska A....NajmoA8a U. (2010)
260. p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas. (PubMed id 19428789)^{1, 9} Gaiser T....Siegelin M.D. (2009)
261. Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes. (PubMed id 18391986)^{1, 9} Bheda A....Pirisi L. (2008)
262. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. (PubMed id 18645275)^{1, 9} Liu L....Guo H. (2008)
263. Immunohistochemical expression of p53, MDM2, and p21Waf1 oncoproteins in endometriomas but not adenomyosis. (PubMed id 15866118)^{1, 9} Goumenou A....Arici A. (2005)
264. Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder. (PubMed id 14756544)^{1, 9} El-Kenawy A.e.l.-.M....Khalil A.M. (2003)
265. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. (PubMed id 12068014)^{1, 9} Jin Y....Lu H. (2002)
266. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation. (PubMed id 11328884)^{1, 9} Kaku S....Kulesz-Martin M. (2001)
267. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. (PubMed id 10781812)^{1, 9} Burch L.R....Hupp T.R. (2000)
268. Clinical significance of p53 and bcl-2 protein coexpression phenotypes in molecular breast cancer subtypes of pre-menopausal and pos t-menopausal African-American women. (PubMed id 19774948)^{1, 9} Ihemelandu C.U....Frederick W.A. (2009)
269. p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. (PubMed id 19048622)^{1, 9} Varna M....Bertheau P. (2009)
270. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). (PubMed id 19096301)^{1, 9} Lim E.H....Tan P. (2009)
271. Expression of p14ARF, p16INK4a and p53 in relation to HPV in (pre-)malignant squamous skin tumours. (PubMed id 18681909)^{1, 9} KA1sters-Vandevelde H.V....Blokx W.A. (2009)
272. FAK overexpression and p53 mutations are highly corre lated in human breast cancer. (PubMed id 19521985)^{1, 9} Golubovskaya V.M....Cance W.G. (2009)
273. P53 and vascular endothelial growth factor expression s are two important indices for prognosis in gastric carcinoma. (PubMed id 19565930)^{1, 9} Guo R....Gu C. (2008)
274. [Mutations of p53 gene in 41 cases of human brain gliomas] (PubMed id 18184456)^{1, 9} Cui W....Wang X.C. (2008)
275. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. (PubMed id 18948956)^{1, 9} Zheng H....DePinho R.A. (2008)
276. Clinical significance of p53 alterations in surgically treated prostate cancers. (PubMed id 18552821)^{1, 9} Schlomm T....Erbersdobler A. (2008)
277. Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients. (PubMed id 17595776)^{1, 9} Bau D.T....Tsai F.J. (2007)
278. Expression of p53 and its homolog, p73, in HPV DNA positive oesophageal squamous cell carcinomas. (PubMed id 17761206)^{1, 9} Matsha T....Parker M.I. (2007)
279. RB1 and TP53 pathways in radiation-induced sarcomas. (PubMed id 17369843)^{1, 9} Gonin-Laurent N....Malfoy B. (2007)
280. Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. (PubMed id 17982625)^{1, 9} Hu T.H....Tai M.H. (2007)
281. Relationship between p53 and p27 expression following HER2 signaling. (PubMed id 17604627)^{1, 9} Casalini P....Menard S. (2007)
282. Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. (PubMed id 16984978)^{1, 9} Maluf F.C....Bajorin D.F. (2006)
283. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. (PubMed id 16624812)^{1, 9} Ohkubo S....Prives C. (2006)
284. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). (PubMed id 16537920)^{1, 9} Zhao Y....Zhu W.G. (2006)
285. Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix. (PubMed id 15832769)^{1, 9} Soufla G....Spandidos D.A. (2005)
286. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. (PubMed id 14680497)^{1, 9} Yamashita H....Iwase H. (2004)
287. Alterations of p53, Bcl-2, and hMSH2 protein expression in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas in the upper Egypt. (PubMed id 15467428)^{1, 9} Hussein M.R. and Ismael H.H. (2004)
288. Co-overexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. (PubMed id 14529662)^{1, 9} Grace V.M....Devaraj H. (2003)
289. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. (PubMed id 12562237)^{1, 9} Chang C.C....Perkins S.L. (2003)
290. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. (PubMed id 14612423)^{1, 9} Dornan D....Hupp T.R. (2003)
291. Expression of bax and p53 proteins in the tumorigenesis and progression of breast carcinomas. (PubMed id 12743423)^{1, 9} Redondo M....Morell M. (2003)
292. Mutations in the p53 tumor suppressor gene and early onset breast cancer. (PubMed id 12170762)^{1, 9} Lai H....Meng L. (2002)
293. Clinical prognostic values of vascular endothelial growth factor, microvessel density,and p53 expression in esophageal carcinomas. (PubMed id 11961303)^{1, 9} Ahn M.J....Park C.K. (2002)
294. [Significance of COX-2, p53, proliferating cell nuclear antigen and nm23 expressions in gastric cancer and its behavior] (PubMed id 12452062)^{1, 9} Ji S.Q....Shao Y.F. (2002)
295. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. (PubMed id 11238924)^{1, 9} Gaiddon C....Prives C. (2001)
296. MDM2 and MDMX can interact differently with ARF and members of the p53 family. (PubMed id 11223036)^{1, 9} Wang X....Poon R.Y. (2001)
297. Hdmx stabilizes Mdm2 and p53. (PubMed id 10827196)^{1, 9} Stad R....Jochemsen A.G. (2000)
298. A common gain of function of p53 cancer mutants in in ducing genetic instability. (PubMed id 19881536)^{1, 9} Liu D.P....Xu Y. (2010)
299. p16INK4a hypermethylation and p53, p16 and MDM2 prote in expression in esophageal squamous cell carcinoma. (PubMed id 20388212)^{1, 9} Taghavi N....Abbaszadegan M.R. (2010)
300. The expression and significance of IDH1 and p53 in os teosarcoma. (PubMed id 20459648)^{1, 9} Hu X....Xu J.H. (2010)
301. CDKN2A but not TP53 mutations nor HPV presence predic t poor outcome in metastatic squamous cell carcinoma of the skin. (PubMed id 19739123)^{1, 9} KA1sters-Vandevelde H.V....Blokx W.A. (2010)
302. Transformation of pleomorphic adenoma to carcinoma ex pleomorphic adenoma of the parotid gland is independent of p53 mutations. (PubMed id 19950209)^{1, 9} Gedlicka C....Thurnher D. (2010)
303. Comparative analysis of P16 and P53 expression in ute rine malignant mixed mullerian tumors. (PubMed id 19851197)^{1, 9} Buza N. and Tavassoli F.A. (2009)
304. Association of polymorphisms in APOE, p53, and p21 wi th primary open-angle glaucoma in Turkish patients. (PubMed id 19578553)^{1, 9} Saglar E....Ogus A. (2009)
305. Predicting positive p53 cancer rescue regions using M ost Informative Positive (MIP) active learning. (PubMed id 19756158)^{1, 9} Danziger S.A....Lathrop R.H. (2009)
306. Significance of p53 and CD31 in astrogliomas. (PubMed id 18821037)^{1, 9} Khattab A.Z....Essa W.A. (2009)
307. Her-2/neu, p-53, and their coexpression in osteosarcoma. (PubMed id 19346874)^{1, 9} Bakhshi S....Rastogi S. (2009)
308. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. (PubMed id 19336573)^{1, 9} Holstege H....Jonkers J. (2009)
309. FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging. (PubMed id 19437562)^{1, 9} Ji F....Chen Y.L. (2009)
310. Gambogic acid reduced bcl-2 expression via p53 in hum an breast MCF-7 cancer cells. (PubMed id 19582475)^{1, 9} Gu H....Guo Q. (2009)
311. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. (PubMed id 19193430)^{1, 9} Ashton K.A....Scott R.J. (2009)
312. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition. (PubMed id 19507240)^{1, 9} Carotti A....Pellicciari R. (2009)
313. p53 Mutation in histologically normal mucosa of the aero-digestive tract is not a marker of increased risk for second primary carcinoma in head and neck cancer patients. (PubMed id 18688630)^{1, 9} Escher A....Monnier P. (2009)
314. P53 and BCL-2 as prognostic markers in endometrial carcinoma. (PubMed id 18398703)^{1, 9} Appel M.L....Dos Reis R. (2008)
315. Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer. (PubMed id 19048399)^{1, 9} Akkiprik M....Ozer A. (2008)
316. Association study of TP53 polymorphisms with lung cancer in a Korean population. (PubMed id 18363031)^{1, 9} Jung H.Y....Kim Y.H. (2008)
317. Common Polymorphisms in the MDM2 and TP53 Genes and the Relationship between TP53 Mutations and Patient Outcomes in Glioblastomas. (PubMed id 18462472)^{1, 9} Zawlik I....Ohgaki H. (2008)
318. Immunohistochemical evaluation of androgen receptor, HER-2/neu, and p53 in benign pleomorphic adenomas. (PubMed id 19061288)^{1, 9} DeRoche T.C....Hunt J.L. (2008)
319. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. (PubMed id 18223210)^{1, 9} Westra W.H....Koch W.M. (2008)
320. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding. (PubMed id 18260640)^{1, 9} Patel S....Nikolova P.V. (2008)
321. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women. (PubMed id 18568671)^{1, 9} Talley L....Frost A.R. (2008)
322. p53 regulates cellular responses to environmental carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide in human lung cancer cells. (PubMed id 17630511)^{1, 9} Xiao H. and Singh S.V. (2007)
323. Expression of Gadd45a and p53 proteins in human pancreatic cancer: potential effects on clinical outcomes. (PubMed id 17230496)^{1, 9} Dong M....Dong Y. (2007)
324. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway. (PubMed id 17823933)^{1, 9} Zhang A.L....Milross C. (2007)
325. Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis. (PubMed id 17488404)^{1, 9} Nindl I....Forschner T. (2007)
326. Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas. (PubMed id 17695524)^{1, 9} Bai M....Kanavaros P. (2007)
327. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. (PubMed id 17259658)^{1, 9} Mollevi D.G....Villanueva A. (2007)
328. Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity. (PubMed id 17275163)^{1, 9} Shang D....Ogawa O. (2007)
329. Breast-cancer stromal cells with TP53 mutations and nodal metastases. (PubMed id 18094375)^{1, 9} Patocs A....Eng C. (2007)
330. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. (PubMed id 17289876)^{1, 9} Libe R....Bertherat J. (2007)
331. P53 gene mutations in pituitary carcinomas. (PubMed id 18026859)^{1, 9} Tanizaki Y....Lloyd R.V. (2007)
332. Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray. (PubMed id 16481301)^{1, 9} Xu L....Gao H.J. (2006)
333. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer. (PubMed id 16839413)^{1, 9} Tsutsui S....Era S. (2006)
334. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. (PubMed id 16847810)^{1, 9} Fijol/ek J....Roszkowski K. (2006)
335. Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease. (PubMed id 16697770)^{1, 9} Lee Y.L....Wang Y.C. (2006)
336. Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id: 8962091628764582. (PubMed id 16686942)^{1, 9} Chaube A....Shukla H.S. (2006)
337. [The expression of p53, p16, cyclin D1 in esophageal squamous cell carcinoma and esophageal dysplasia] (PubMed id 17060721)^{1, 9} Kim S.G....Kim B.S. (2006)
338. p53 mediates the negative regulation of MDM2 by orphan receptor TR3. (PubMed id 17139261)^{1, 9} Zhao B.X....Wu Q. (2006)
339. The central region of HDM2 provides a second binding site for p53. (PubMed id 16432196)^{1, 9} Yu G.W....Fersht A.R. (2006)
340. Expression of p53 and p21 in primary glioblastomas. (PubMed id 15756520)^{1, 9} Gross M.W....Schlegel J. (2005)
341. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. (PubMed id 15583825)^{1, 9} Menendez J.A. and Lupu R. (2005)
342. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. (PubMed id 15843377)^{1, 9} Mayo L.D....Donner D.B. (2005)
343. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. (PubMed id 15764647)^{1, 9} Hastak K....Agarwal M.L. (2005)
344. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. (PubMed id 16354195)^{1, 9} Yang G....Tsao H. (2005)
345. Higher expressions of p53 and proliferating cell nuclear antigen (PCNA) in atrophic oral lichen planus and patients with areca quid chewing. (PubMed id 15772596)^{1, 9} Lee J.J....Kok S.H. (2005)
346. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines. (PubMed id 15830705)^{1, 9} Lun M....Brown R.E. (2005)
347. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. (PubMed id 14961077)^{1, 9} Wang Y....Mischel P.S. (2004)
348. Distinct functions for WRN and TP53 in a shared pathway of cellular response to 1-beta-D-arabinofuranosylcytosine and bleomycin. (PubMed id 15149862)^{1, 9} Poot M....Rabinovitch P.S. (2004)
349. Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. (PubMed id 15116093)^{1, 9} Yeh P.Y....Cheng A.L. (2004)
350. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. (PubMed id 14701769)^{4, 9} Bull S.B....Andrulis I.L. (2004)
351. p53 expression and p21 expression are mutually exclusive in esophageal squamous cell carcinoma. (PubMed id 14654903)^{1, 9} Hamada M....Tanaka N. (2004)
352. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. (PubMed id 15170665)^{1, 9} Sohda M....Kuwano H. (2004)
353. Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. (PubMed id 12642871)^{1, 9} Ohtsuka T....Lee S.W. (2003)
354. Increased mdm-2 expression in a p53-independent manner blocks UV-induced cell cycle arrest and apoptosis in human osteosarcoma cells. (PubMed id 14610316)^{1, 9} Dong Y.B....McMasters K.M. (2003)
355. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. (PubMed id 12809883)^{1, 9} Shariat S.F....Lerner S.P. (2003)
356. Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma? (PubMed id 12800224)^{1, 9} Sheen I.S....Wu J.Y. (2003)
357. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene. (PubMed id 14710355)^{1, 9} Abramovitch S. and Werner H. (2003)
358. Induction of p53-dependent activation of the human proliferating cell nuclear antigen gene in chromatin by ionizing radiation. (PubMed id 12947108)^{1, 9} Shan B....Morris G.F. (2003)
359. [Expression of bcl-2, c-erbB2, and p53 protein in cer vical epithelial carcinogenesis] (PubMed id 14558950)^{1, 9} Tang Z.H....Ye X.A. (2003)
360. Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas. (PubMed id 12969350)^{1, 9} Chen Y.K....Lin L.M. (2003)
361. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. (PubMed id 12208736)^{1, 9} Leung K.M....Poon R.Y. (2002)
362. [Expressions of beta-catenin, p53 and proliferating cell nuclear antigen in the carcinogenesis of colorectal adenoma] (PubMed id 12515622)^{1, 9} Wu W....Li Y. (2002)
363. MDMX inhibits the p300/CBP-mediated acetylation of p53. (PubMed id 12162806)^{1, 9} Sabbatini P. and McCormick F. (2002)
364. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. (PubMed id 11844810)^{1, 9} Yuan A....Yang P.C. (2002)
365. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. (PubMed id 12607601)^{1, 9} Sun W....Herrera G.A. (2002)
366. Analysis of p53 tumor suppressor gene in families with multiple glioma patients. (PubMed id 11859970)^{1, 9} Paunu N....Haapasalo H. (2001)
367. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. (PubMed id 11278647)^{1, 9} Grigorian M....Lukanidin E. (2001)
368. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. (PubMed id 11309330)^{4, 9} Buller R.E....Kirby P.A. (2001)
369. Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? (PubMed id 11255264)^{1, 9} Bastiaens M.T....ter Schegget J. (2001)
370. Distant metastases in ovarian cancer: association with p53 mutations. (PubMed id 10499623)^{4, 9} Sood A.K....Buller R.E. (1999)
371. p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. (PubMed id 9492043)^{1, 9} Ohlsson C....LeRoith D. (1998)
372. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. (PubMed id 9416838)^{4, 9} de Anta J.M....Sanchez-Cespedes M. (1997)
373. Association between p53 mutation and clinicopathological features of non-small cell lung cancer. (PubMed id 9379505)^{4, 9} Guang S.G....Nagai K. (1997)
374. Differentiated vulvar intraepithelial neoplasia conta ins Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma. (PubMed id 20062014)^{1, 9} Pinto A.P....Crum C.P. (2010)
375. Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic. (PubMed id 20110284)^{1, 9} Naccarati A....Vodicka P. (2010)
376. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. (PubMed id 20520810)^{1, 9} Fang S....Amos C.I. (2010)
377. Estrogen receptor acting in cis enhances WT and mutan t p53 transactivation at canonical and noncanonical p53 target sequences. (PubMed id 20080630)^{1, 9} Menendez D....Resnick M.A. (2010)
378. [Analysis of the P53 transcriptional activity in gast ric cancer] (PubMed id 20140870)^{1, 9} Zhu Y....Bi F. (2010)
379. Systematic review and meta-analysis of the associatio n between P53 codon 72 polymorphism and colorectal cancer. (PubMed id 20363586)^{1, 9} Tang N.P....Ma J. (2010)
380. Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neopl asia (PanIN). (PubMed id 20350215)^{1, 9} Karamitopoulou E....Terracciano L. (2010)
381. Combined detection of p53, p16, Rb, and EGFR mutation s in lung cancer by suspension microarray. (PubMed id 20082263)^{1, 9} Ye Y....Guo A. (2009)
382. Correlation between histological type and immunohisto chemical profile of prostate cancer and gleason scale gradation. (PubMed id 20010526)^{1, 9} Iemelynova A.A....Romanenko A.M. (2009)
383. Structural evolution of p53, p63, and p73: implicatio n for heterotetramer formation. (PubMed id 19815500)^{1, 9} Joerger A.C....Fersht A.R. (2009)
384. Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines. (PubMed id 19217709)^{1, 9} Duarte M.L....Ferreira C.G. (2009)
385. The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract. (PubMed id 19153488)^{1, 9} Oki E....Maehara Y. (2009)
386. Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. (PubMed id 19876867)^{1, 9} Anselmo N.P....Casartelli C. (2009)
387. p53 controls cancer cell invasion by inducing the MDM 2-mediated degradation of Slug. (PubMed id 19448627)^{1, 9} Wang S.P....Yang P.C. (2009)
388. [Upregulation of survivin in non-small cell lung canc er and its clinicopathological correlation with p53 and Bcl-2] (PubMed id 19664395)^{1, 9} Han P.H....Ren H. (2009)
389. Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status. (PubMed id 19208263)^{1, 9} Ha S.A....Kim J.W. (2009)
390. The prevalence of germ-line TP53 mutations in women d iagnosed with breast cancer before age 30. (PubMed id 19714488)^{1, 9} Ginsburg O.M....Narod S.A. (2009)
391. Hypoxia-induced decrease in p53 protein level and inc rease in c-jun DNA binding activity results in cancer cell resistance to etopos ide. (PubMed id 19794957)^{1, 9} Cosse J.P....Michiels C. (2009)
392. [Overexpression and higher phosphorylation of p53 induced by benzo(a) pyrene through activated protein 1 independent pathway] (PubMed id 18646516)^{1, 9} Ye M....Gao A. (2008)
393. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. (PubMed id 18339852)^{1, 9} Li Y....Abounader R. (2008)
394. Expression of p16 and cervical infection with high-risk human papillomavirus are not related to p53 activity in cervical intraepithelial neoplasia. (PubMed id 18021213)^{1, 9} BraganAsa J.F....Derchain S. (2008)
395. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer] (PubMed id 18788631)^{1, 9} Tan X.J....Xu X.Y. (2008)
396. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. (PubMed id 18172861)^{1, 9} Lee T.L....Chen Z. (2008)
397. The clinicopathological roles of alpha-B-crystallin and p53 expression in patients with head and neck squamous cell carcinoma. (PubMed id 18604737)^{1, 9} Boslooper K....Johnson N. (2008)
398. Tissue array for Tp53, C-myc, CCND1 gene over-expression in different tumors. (PubMed id 19084934)^{1, 9} Liu G.Y....Gao H.Z. (2008)
399. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. (PubMed id 18331779)^{1, 9} Kanellou P....Spandidos D.A. (2008)
400. [Expression of Survivin, Caspase-3 and p53 in surgical margin of laryngeal squamous cell carcinoma and their relationship] (PubMed id 18476631)^{1, 9} Du J....Su Y. (2008)
401. Genetic polymorphisms, messenger RNA expression of p53, p21, and CCND1, and possible links with chromosomal aberrations in Chinese vinyl chloride-exposed workers. (PubMed id 18842998)^{1, 9} Qiu Y.L....Xia Z.L. (2008)
402. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. (PubMed id 18639569)^{1, 9} Simoes M.L....Arlt V.M. (2008)
403. p53 Binding to the p21 promoter is dependent on the nature of DNA damage. (PubMed id 18719376)^{1, 9} Hill R....Lee P.W. (2008)
404. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. (PubMed id 17242401)^{1, 9} Sun X.X....Lu H. (2007)
405. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. (PubMed id 17151932)^{1, 9} Malmer B.S....Henriksson R. (2007)
406. Expression of p53, p16 and cyclooxygenase-2 in esophageal cancer with tissue microarray. (PubMed id 17650224)^{1, 9} Liu Y.S....Jun Gao H. (2007)
407. [p53 Codon 72 and 16-bp duplication polymorphisms of gastric cancer in Koreans] (PubMed id 18159160)^{1, 9} Kim J.M....Lee D.H. (2007)
408. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer. (PubMed id 17221157)^{1, 9} Ozcelik H....Andrulis I.L. (2007)
409. Loss of heterozygosity of the p53 gene and deregulated expression of its mRNA and protein in human brain tumors. (PubMed id 17180249)^{1, 9} Rohini K....Gope R. (2007)
410. [Association of p16, p53, Ki-67 expressions with high-risk human papilloma virus infection in cervical intraepithelial neoplasia] (PubMed id 17545048)^{1, 9} Shi J....Zhou X.L. (2007)
411. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. (PubMed id 17401424)^{1, 9} Petitjean A....Olivier M. (2007)
412. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele. (PubMed id 17982662)^{1, 9} Chung S.M....Chen Y.T. (2007)
413. Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. (PubMed id 19034345)^{1, 9} Ismail H.M....Touny A. (2007)
414. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? (PubMed id 17622940)^{1, 9} Tan X.L....Chang-Claude J. (2007)
415. [Association of p53 polymorphisms and its haplotypes with susceptibility of breast cancer] (PubMed id 18067229)^{1, 9} Zhang W....Chen K. (2007)
416. Hepatitis C virus F protein up-regulates c-myc and down-regulates p53 in human hepatoma HepG2 cells. (PubMed id 17700029)^{1, 9} Wu W.B....Qi Z.T. (2007)
417. p73 and MDM2 confer the resistance of epidermoid carcinoma to cisplatin by blocking p53. (PubMed id 16815295)^{1, 9} Hayashi S....Nakagawara A. (2006)
418. Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. (PubMed id 17091766)^{1, 9} Porebska I....Harl/ozinska-Szmyrka A. (2006)
419. [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms] (PubMed id 16750013)^{1, 9} Yuan P....Lin D.X. (2006)
420. L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. (PubMed id 16861890)^{1, 9} Banks D....Zhang H. (2006)
421. Association of breast cancer outcome with status of p53 and MDM2 SNP309. (PubMed id 16818855)^{1, 9} Boersma B.J....Ambs S. (2006)
422. p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. (PubMed id 16835330)^{1, 9} Rohan T.E....Kandel R.A. (2006)
423. Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair. (PubMed id 17030796)^{1, 9} Feng Z....Tang M.S. (2006)
424. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. (PubMed id 16601753)^{1, 9} Murray-Zmijewski F....Bourdon J.C. (2006)
425. TP53 gene mutations are rare in nondysplastic Barrett's esophagus. (PubMed id 16416221)^{1, 9} Novotna K....Sedlacek Z. (2006)
426. Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. (PubMed id 16327987)^{1, 9} Park C.M....Hong S.I. (2006)
427. Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. (PubMed id 16489641)^{1, 9} Tian Y....Wu S.D. (2006)
428. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. (PubMed id 16469747)^{1, 9} Liu W....Das G.M. (2006)
429. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. (PubMed id 16169726)^{1, 9} Cho M.H....Min K.W. (2006)
430. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. (PubMed id 16644204)^{1, 9} Lalloo F....Evans D.G. (2006)
431. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. (PubMed id 16434604)^{1, 9} Schabath M.B....Spitz M.R. (2006)
432. Association between DNA repair gene polymorphisms and p53 alterations in Japanese patients with muscle-invasive bladder cancer. (PubMed id 17374967)^{1, 9} Sakano S....Naito K. (2006)
433. Role of Stat3 in regulating p53 expression and function. (PubMed id 16107692)^{1, 9} Niu G....Yu H. (2005)
434. TP53 alterations and patterns of carcinogen exposure in a U.S. population-based study of bladder cancer. (PubMed id 15906354)^{1, 9} Kelsey K.T....Karagas M. (2005)
435. [Association of the p53 codon 72 polymorphism to gastric cancer risk in a hight risk population of Costa Rica] (PubMed id 17354442)^{1, 9} Alpizar-Alpizar W....Perez-Perez G.I. (2005)
436. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. (PubMed id 16107691)^{1, 9} Ho J.S....Benchimol S. (2005)
437. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. (PubMed id 15702478)^{1, 9} Calistri D....Amadori D. (2005)
438. Alterations of p53, cyclin D1 and pRB expression in the carcinogenesis of esophageal squamous cell carcinoma. (PubMed id 16273238)^{1, 9} Kawakubo H....Kitajima M. (2005)
439. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. (PubMed id 15564800)^{1, 9} Hedau S....Das B.C. (2004)
440. Differences in p53 gene polymorphisms between Korean schizophrenia and lung cancer patients. (PubMed id 14741326)^{1, 9} Park J.K....Chung J.H. (2004)
441. Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. (PubMed id 15557124)^{1, 9} Bao W. and Stromblad S. (2004)
442. Presences of human papillomavirus DNA (HPV) and immunohistochemical p53 overexpression in papillomas of oral cavity. (PubMed id 15638389)^{1, 9} Barzal/-Nowosielska M....Chyczewski L. (2004)
443. TP53 codon 72 polymorphism does not affect risk of cervical cancer in patients from The Gambia. (PubMed id 14756543)^{1, 9} Tanara G....Cosimi A. (2003)
444. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer. (PubMed id 12820330)^{1, 9} Ecke T.H....Loening S.A. (2003)
445. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. (PubMed id 12972634)^{1, 9} Overholtzer M....Levine A.J. (2003)
446. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. (PubMed id 14559824)^{1, 9} Zhou M....Woods W.G. (2003)
447. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. (PubMed id 12543796)^{1, 9} Okada Y....Louis D.N. (2003)
448. Caffeine induces G2/M arrest and apoptosis via a novel p53-dependent pathway in NB4 promyelocytic leukemia cells. (PubMed id 12811820)^{1, 9} Ito K....Kizaki M. (2003)
449. Detection of p53 gene mutations by nonisotopic RNase cleavage assay as a predictor of poor prognosis in colorectal cancers. (PubMed id 14627345)^{1, 9} Haseba M....Ayabe H. (2003)
450. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. (PubMed id 12610779)^{1, 9} Hwang S.J....Strong L.C. (2003)
451. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. (PubMed id 12684392)^{1, 9} Berns E.M....Foekens J.A. (2003)
452. p53 Codon 72 polymorphism and urothelial cancer risk. (PubMed id 12445680)^{1, 9} Kuroda Y....Katoh T. (2003)
453. Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. (PubMed id 14583777)^{4, 9} Doak S.H....Parry J.M. (2003)
454. Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells. (PubMed id 12955365)^{1, 9} Hinata N....Gotoh A. (2003)
455. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. (PubMed id 11957139)^{1, 9} Choi H.R....El-Naggar A.K. (2002)
456. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression. (PubMed id 12607595)^{1, 9} Lee J.S....Park C.S. (2002)
457. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma. (PubMed id 12168936)^{1, 9} Peng C.Y....Liaw Y.F. (2002)
458. Clinical significance of expression of p21 and p53 proteins and proliferating cell nuclear antigen in pancreatic cancer. (PubMed id 14612290)^{1, 9} Dang C.X....Wang Y.J. (2002)
459. p53 codon 72 polymorphism and its association with bladder cancer. (PubMed id 11888672)^{1, 9} Soulitzis N....Spandidos D.A. (2002)
460. Prognostic significance of p53 mutations in colon cancer at the population level. (PubMed id 11992552)^{1, 9} Samowitz W.S....Slattery M.L. (2002)
461. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. (PubMed id 11895857)^{1, 9} Baek S.J....Eling T.E. (2002)
462. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. (PubMed id 11893750)^{1, 9} Strano S....Blandino G. (2002)
463. Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. (PubMed id 11751391)^{1, 9} Achanta G....Huang P. (2001)
464. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. (PubMed id 9891077)^{1, 9} Di Como C.J....Prives C. (1999)
465. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. (PubMed id 9926942)^{1, 9} Chai Y.L....Rao V.N. (1999)
466. ATM associates with and phosphorylates p53: mapping the region of interaction. (PubMed id 9843217)^{1, 9} Khanna K.K.... Lavin M.F. (1998)
467. Association of p53 mutations with metastatic prostate cancer. (PubMed id 9815901)^{4, 9} Eastham J.A....Thompson T.C. (1995)
468. Racial disparity in the association of p53 gene alterations with breast cancer survival. (PubMed id 7882357)^{4, 9} Shiao Y.H....Correa P. (1995)
469. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. (PubMed id 7730141)^{4, 9} Nakamori S....Sekiya T. (1995)
470. Immunohistochemical overexpression of the p53 protein and Ki-67 (MIB-1) antigen in patients with GERD and chronic esophagitis. (PubMed id 20414055)^{1, 9} Binato M....Edelweiss M.I. (2010)
471. Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese po pulation. (PubMed id 19238535)^{1, 9} Cao A.Y....Shao Z.M. (2010)
472. Increased expression of the heterogeneous nuclear rib onucleoprotein K in pancreatic cancer and its association with the mutant p53. (PubMed id 19609950)^{1, 9} Zhou R....Shi J. (2010)
473. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma. (PubMed id 20233581)^{1, 9} Schilling T....MA1ller M. (2010)
474. P53 codon 72 polymorphism contributes to breast cance r risk: a meta-analysis based on 39 case-control studies. (PubMed id 19629678)^{1, 9} Zhang Z....Zhang Z. (2010)
475. p53 expression in tumor-stromal fibroblasts is closel y associated with the nodal metastasis and outcome of patients with invasive du ctal carcinoma who received neoadjuvant therapy. (PubMed id 19836055)^{1, 9} Hasebe T....Kinoshita T. (2010)
476. Forodesine has high antitumor activity in chronic lym phocytic leukemia and activates p53-independent mitochondrial apoptosis by indu ction of p73 and BIM. (PubMed id 19541822)^{1, 9} Alonso R....Colomer D. (2009)
477. Mutations in TP53 tumor suppressor gene in wood dust- related sinonasal cancer. (PubMed id 19950227)^{1, 9} Holmila R....Husgafvel-Pursiainen K. (2009)
478. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. (PubMed id 19255450)^{1, 9} Pazgier M....Lu W. (2009)
479. Inactivation of p53 and Pten promotes invasive bladder cancer. (PubMed id 19261747)^{1, 9} Puzio-Kuter A.M....Abate-Shen C. (2009)
480. Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. (PubMed id 19682377)^{1, 9} Zhuo W....Chen Z. (2009)
481. A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. (PubMed id 19426493)^{1, 9} GallA- P....Boccia S. (2009)
482. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. (PubMed id 19050681)^{1, 9} Nariculam J....Feneley M. (2009)
483. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. (PubMed id 19367287)^{1, 9} Oden-Gangloff A....Frebourg T. (2009)
484. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. (PubMed id 19141386)^{1, 9} Ruano Y....MelAcndez B. (2009)
485. Mitochondrial D-loop mutation is a common event in colorectal cancers with p53 mutations. (PubMed id 19198855)^{1, 9} Chang S.C....Lin J.K. (2009)
486. Invasive hydatidiform mole: immunohistochemical label ling of inhibin/activin subunits, Ki67, p53 and glycodelin A in a rare case. (PubMed id 19195690)^{1, 9} Makovitzky J....Mylonas I. (2009)
487. Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. (PubMed id 19103203)^{1, 9} Leedham S.J....Wright N.A. (2009)
488. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. (PubMed id 19816404)^{1, 9} Cheng Q....Chen J. (2009)
489. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activ ation of the EGFR/PI3K/AKT pathway. (PubMed id 19917135)^{1, 9} Dong P....Feng Y. (2009)
490. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. (PubMed id 19543244)^{1, 9} Shaw P.A....Begley H. (2009)
491. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. (PubMed id 19096302)^{1, 9} Kosaka T....Mitsudomi T. (2009)
492. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. (PubMed id 19577853)^{1, 9} Sakiz D....Kabukcuoglu F. (2009)
493. Enhanced sensitivity of celecoxib in human glioblasto ma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. (PubMed id 19706164)^{1, 9} Kang K.B....Wong M.C. (2009)
494. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. (PubMed id 19339276)^{1, 9} Katkoori V.R....Manne U. (2009)
495. Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways. (PubMed id 19267931)^{1, 9} Mizuno S....Ishizaki T. (2009)
496. Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. (PubMed id 18383208)^{1, 9} Bettendorf O....Semjonow A. (2008)
497. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. (PubMed id 18374497)^{1, 9} Terzi A....Soylemezoglu F. (2008)
498. Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous angiosarcoma and pyogenic granuloma. (PubMed id 18700251)^{1, 9} Chen S.Y....Moroi Y. (2008)
499. Head and neck squamous cell carcinoma in non-smoking and non-drinking patients with multiple tumors: etiologic significance of p53 and Ki-67 in non-tumorous epithelium. (PubMed id 18331287)^{1, 9} Farshadpour F....Slootweg P.J. (2008)
500. Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. (PubMed id 18572327)^{1, 9} Gonul I.I....Kupeli B. (2008)
501. Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. (PubMed id 18348141)^{1, 9} Xu Y....Xie Y. (2008)
502. p53 gene alterations and human papillomavirus type 16 infection in early stages of cervical carcinoma in Serbia. (PubMed id 19145674)^{1, 9} Malisic E....Radulovic S. (2008)
503. Arginine methylation regulates the p53 response. (PubMed id 19011621)^{1, 9} Jansson M....La Thangue N.B. (2008)
504. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer. (PubMed id 18367114)^{1, 9} Ecke T.H....Loening S.A. (2008)
505. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells. (PubMed id 18332869)^{1, 9} Qiu W....Xiao Z.X. (2008)
506. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. (PubMed id 18452596)^{1, 9} Oh S.Y....Kim H.J. (2008)
507. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. (PubMed id 18345033)^{1, 9} Toscano F....Saurin J.C. (2008)
508. Utility of thin-layer preparations in endometrial cytology: immunocytochemical expression of PTEN, beta-catenin and p53 for benign endometrial lesions. (PubMed id 18335551)^{1, 9} Norimatsu Y....Ohno E. (2008)
509. Expression of Ki-67, p53 and p63 proteins in keratocyst odontogenic tumours: an immunohistochemical study. (PubMed id 18256893)^{1, 9} Gurgel C.A....dos Santos J.N. (2008)
510. Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. (PubMed id 18091326)^{1, 9} Lee D.Y....Lee S. (2008)
511. Partial proteasome inhibition in human fibroblasts triggers accelerated M1 senescence or M2 crisis depending on p53 and Rb status. (PubMed id 18691182)^{1, 9} Chondrogianni N....Gonos E.S. (2008)
512. Human germline and somatic cells have similar TP53 and Kirsten-RAS gene single base mutation frequencies. (PubMed id 18418864)^{1, 9} Cole D.N....Wilson V.L. (2008)
513. Notch-1 regulates transcription of the epidermal growth factor receptor through p53. (PubMed id 18359760)^{1, 9} Purow B.W....Fine H.A. (2008)
514. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors. (PubMed id 18656689)^{1, 9} Bumroongkit K....Kangwanpong D. (2008)
515. Involvement of the p53 and p73 transcription factors in neuroAIDS. (PubMed id 18719392)^{1, 9} Mukerjee R....Sawaya B.E. (2008)
516. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. (PubMed id 18465328)^{1, 9} Alsner J....Overgaard J. (2008)
517. Arginine methylation of hnRNP K enhances p53 transcriptional activity. (PubMed id 18472002)^{1, 9} Chen Y....Hu G. (2008)
518. Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events. (PubMed id 19005564)^{1, 9} Chen Z....Sommer S.S. (2008)
519. Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: the potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation. (PubMed id 18829481)^{1, 9} Huang H.Y....Li C.F. (2008)
520. Reduced membranous beta-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus. (PubMed id 18455580)^{1, 9} Hsu P.K....Hsu H.S. (2008)
521. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation. (PubMed id 18234963)^{1, 9} Malaguarnera R....Frasca F. (2008)
522. [Peripheral blood p53 single nucleotide polymorphism analysis for early diagnosis of colorectal carcinoma] (PubMed id 18159026)^{1, 9} Liu Q....Zhou M. (2007)
523. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. (PubMed id 17426704)^{1, 9} Nehls O....Klump B. (2007)
524. Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours. (PubMed id 17216584)^{1, 9} Armstrong J.L....Lovat P.E. (2007)
525. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. (PubMed id 17504517)^{1, 9} Langerod A....Jeffrey S.S. (2007)
526. The role of p53, Bcl-2 and Ki-67 in premalignant cervical lesions and cervical cancer. (PubMed id 17713095)^{1, 9} Turkcuoglu I....Sertcelik A. (2007)
527. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. (PubMed id 17575133)^{1, 9} Mounawar M....Hainaut P. (2007)
528. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. (PubMed id 17200338)^{1, 9} Chang Y.L....Lee Y.C. (2007)
529. A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. (PubMed id 17908957)^{1, 9} Lee T.L....Chen Z. (2007)
530. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. (PubMed id 17699779)^{1, 9} Sayeed A....Das G.M. (2007)
531. p53 Family isoforms. (PubMed id 18289041)^{1, 9} Bourdon J.C. (2007)
532. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. (PubMed id 17545525)^{1, 9} Sanchez-Carbayo M....Cordon-Cardo C. (2007)
533. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. (PubMed id 17388661)^{1, 9} Bertheau P....de The H. (2007)
534. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. (PubMed id 17363555)^{1, 9} Weisz L....Oren M. (2007)
535. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. (PubMed id 17693666)^{1, 9} Chen K....Wei Q. (2007)
536. Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age. (PubMed id 17567834)^{1, 9} Trkova M....Sedlacek Z. (2007)
537. Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas. (PubMed id 17390041)^{1, 9} Yakut T....Schulten H.J. (2007)
538. Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression. (PubMed id 17982131)^{1, 9} Sanchez-Carbayo M....Cordon-Cardo C. (2007)
539. Contribution of p16INK4a and p21CIP1 pathways to induction of premature senescence of human endothelial cells: permissive role of p53. (PubMed id 16243918)^{1, 9} Chen J....Goligorsky M.S. (2006)
540. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. (PubMed id 16432214)^{1, 9} Menendez D....Schonfelder G. (2006)
541. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. (PubMed id 16951228)^{1, 9} Sumiyoshi Y....Maehara Y. (2006)
542. GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. (PubMed id 16446369)^{1, 9} Yan W. and Chen X. (2006)
543. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. (PubMed id 16778101)^{1, 9} Okumura H....Aikou T. (2006)
544. Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. (PubMed id 16760301)^{1, 9} Bazan V....Russo A. (2006)
545. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. (PubMed id 16818665)^{1, 9} Gormally E....Hainaut P. (2006)
546. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. (PubMed id 16541312)^{1, 9} Wasielewski M....Schutte M. (2006)
547. Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. (PubMed id 16094622)^{1, 9} Gwosdz C....Balz V. (2006)
548. Platelet-activating factor-induced NF-kappaB activation enhances VEGF expression through a decrease in p53 activity. (PubMed id 16684540)^{1, 9} Ko H.M....Im S.Y. (2006)
549. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. (PubMed id 16499995)^{1, 9} Szymanowska A....Jassem J. (2006)
550. Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation. (PubMed id 15782125)^{1, 9} Bergamaschi D....Lu X. (2005)
551. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer. (PubMed id 15917726)^{1, 9} Bozcuk H....Savas B. (2005)
552. TP53 mutation, allelism and survival in non-small cell lung cancer. (PubMed id 15905205)^{1, 9} Nelson H.H....Kelsey K.T. (2005)
553. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. (PubMed id 16203773)^{1, 9} Mandic R....Werner J.A. (2005)
554. Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes. (PubMed id 15856024)^{1, 9} Ceballos E....Leon J. (2005)
555. Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315. (PubMed id 16037820)^{1, 9} Fogal V....Lu X. (2005)
556. Constitutive IL-8 expression in cancer cells is associated with mutation of p53. (PubMed id 15945132)^{1, 9} Hidaka H....Ogawa M. (2005)
557. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) exhibits p53-dependent and -independent antiproliferative activity in human nasopharyngeal carcinoma cells in vitro and in vivo. (PubMed id 16142332)^{1, 9} Nguyen T.H....Huynh H. (2005)
558. Relief of p53-mediated telomerase suppression by p73. (PubMed id 15734740)^{1, 9} Toh W.H....Sabapathy K. (2005)
559. p53, Bcl-2 and C-Myc expressions in colorectal carcinoma associated with schistosomiasis in Egypt. (PubMed id 16308474)^{1, 9} Zalata K.R....Leech S.H. (2005)
560. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. (PubMed id 16354872)^{1, 9} Jain N....Das B.C. (2005)
561. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer. (PubMed id 16101161)^{1, 9} Yoshimatsu T....Yasumoto K. (2005)
562. Expression of cellular FLICE-inhibitory protein and its association with p53 mutation in colon cancer. (PubMed id 15832422)^{1, 9} Zhou X.D....Luo H.S. (2005)
563. The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma. (PubMed id 16273227)^{1, 9} Lagerstedt K.K....Lundholm K. (2005)
564. Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma. (PubMed id 16358373)^{1, 9} Zhao D.P....Zhang S.Z. (2005)
565. Immunohistochemical study of vascular endothelial growth factor (VEGF), tumor suppressor protein (p53) and intercellular adhesion molecule (ICAM-1) in the conjunctiva of diabetic patients. (PubMed id 16482425)^{1, 9} Kria L....Ouertani A.M. (2005)
566. Comparative assessment of the functional p53 status in glioma cells. (PubMed id 15816541)^{1, 9} Kim E.L....Giese A. (2005)
567. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. (PubMed id 15297421)^{1, 9} Bali A....Henshall S.M. (2004)
568. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma. (PubMed id 15310147)^{1, 9} Park H.R....Park Y.K. (2004)
569. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. (PubMed id 15448009)^{1, 9} Pakos E.E....Ioannidis J.P. (2004)
570. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. (PubMed id 14576150)^{1, 9} Tang C.H. and Grimm E.A. (2004)
571. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. (PubMed id 15069555)^{1, 9} Shen H....Wei Q. (2004)
572. Association of p53 arginine polymorphism with skin cancer. (PubMed id 15230885)^{1, 9} de Oliveira W.R....Tyring S.K. (2004)
573. Chromosome 10 and 17 deletions and p53 gene mutations in Thai patients with astrocytomas. (PubMed id 14654927)^{1, 9} Put-Ti-Noi S....Thangnipon W. (2004)
574. Beta-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. (PubMed id 15111320)^{1, 9} Saegusa M....Okayasu I. (2004)
575. Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis. (PubMed id 14676844)^{1, 9} Gu J....Fang B. (2004)
576. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. (PubMed id 15355915)^{1, 9} Jones J.S....Frazier M.L. (2004)
577. Elevated expression of DNA polymerase kappa in human lung cancer is associated with p53 inactivation: Negative regulation of POLK promoter activity by p53. (PubMed id 15202001)^{1, 9} Wang Y....O-Wang J. (2004)
578. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. (PubMed id 14634213)^{1, 9} Asher G....Shaul Y. (2003)
579. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. (PubMed id 14693272)^{1, 9} Pagliaro L.C....Dinney C.P. (2003)
580. Correlated expression of inducible nitric oxide synthase and P53, Bax in benign and malignant diseased gallbladder. (PubMed id 14704000)^{1, 9} Zhang M....Kuhnel W. (2003)
581. Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells. (PubMed id 12609716)^{1, 9} Harada H....Ohnishi T. (2003)
582. Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan. (PubMed id 12635827)^{1, 9} Chen Y.C....Christiani D.C. (2003)
583. Doxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines. (PubMed id 12698197)^{1, 9} Liem A.A....Thompson A.M. (2003)
584. Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. (PubMed id 12875991)^{1, 9} Gallo O....Capaccioli S. (2003)
585. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. (PubMed id 12749011)^{1, 9} Sohn S.K....Lee K.B. (2003)
586. Mutation of the p53 gene predicts lymph node metastases in Japanese patients with esophageal carcinoma: DNA and immunohistochemical analyses. (PubMed id 14641293)^{1, 9} Hattori K....Tsurumaru M. (2003)
587. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. (PubMed id 14675665)^{1, 9} Tsuda H....Yamamoto K. (2003)
588. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. (PubMed id 14612499)^{1, 9} Fraser M....Tsang B.K. (2003)
589. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. (PubMed id 14581358)^{1, 9} Bonafe M....Franceschi C. (2003)
590. G2 arrest in response to topoisomerase II inhibitors: the role of p53. (PubMed id 12874009)^{1, 9} Clifford B....Taylor W.R. (2003)
591. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. (PubMed id 12668287)^{1, 9} Nakayama K....Miyazaki K. (2003)
592. Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer. (PubMed id 12174901)^{1, 9} Cassano A....Barone C. (2002)
593. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. (PubMed id 11929815)^{4, 9} Conway K....Newman B. (2002)
594. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. (PubMed id 11779855)^{1, 9} Lorenzo E....Redondo J.M. (2002)
595. HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. (PubMed id 12144822)^{1, 9} Saranath D....Dinshaw K. (2002)
596. Association of p53 gene mutation and telomerase activity in resectable non-small cell lung cancer. (PubMed id 11502663)^{4, 9} Maniwa Y....Okita Y. (2001)
597. Association between DNA repair-deficiency and high level of p53 mutations in melanoma of Xeroderma pigmentosum. (PubMed id 11289118)^{4, 9} Spatz A....Sarasin A. (2001)
598. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. (PubMed id 11528400)^{1, 9} Parant J....Lozano G. (2001)
599. Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. (PubMed id 11146230)^{1, 9} Peixoto Guimaraes D....Hainaut P. (2001)
600. Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. (PubMed id 11949842)^{1, 9} Hsia J.Y....Chen J.T. (2001)
601. The p53 gene in patients under the age of 40 with gastric cancer: mutation rates are low but are associated with a cardiac location. (PubMed id 11040944)^{4, 9} Rugge M....Egarter-Vigl E. (2000)
602. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. (PubMed id 9635853)^{4, 9} Uchida S....Imamura M. (1998)
603. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. (PubMed id 9421363)^{4, 9} Soong R....Robbins P.D. (1997)
604. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. (PubMed id 8986812)^{1, 9} Walker K.K. and Levine A.J. (1996)
605. Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer. (PubMed id 8640913)^{4, 9} Romkes M....Branch R.A. (1996)
606. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. (PubMed id 8564971)^{4, 9} Perego P....Zunino F. (1996)
607. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. (PubMed id 7854378)^{4, 9} Brennan J.A....Sidransky D. (1995)
608. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. (PubMed id 8100564)^{4, 9} Ito T....Akiyama M. (1993)
609. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. (PubMed id 2216456)^{4, 9} Stratton M.R....Gusterson B.A. (1990)
610. Alternative splicing of p53 and p73: the novel p53 sp lice variant p53delta is an independent prognostic marker in ovarian cancer. (PubMed id 20101229)^{1, 9} Hofstetter G....Zeillinger R. (2010)
611. Decreased p21 expression in HPV-18 positive cervical carcinomas. (PubMed id 19657726)^{1, 9} Huang L.W....Chen H.J. (2010)
612. Selenite triggers rapid transcriptional activation of p53, and p53-mediated apoptosis in prostate cancer cells: Implication for the treatment of early-stage prostate cancer. (PubMed id 20428765)^{1, 9} Sarveswaran S....Ghosh J. (2010)
613. MIB-1 (Ki-67), estrogen receptor, progesterone recept or, and p53 expression in atypical cells in uterine symplastic leiomyomas. (PubMed id 19952937)^{1, 9} Sun X. and Mittal K. (2010)
614. p53 gene mutations and codon 72 polymorphism in ovari an carcinoma patients from Serbia. (PubMed id 20414935)^{1, 9} Malisic E....Radulovic S. (2010)
615. Evaluation of the frequency of TP53 gene codon 72 pol ymorphisms in Iranian patients with endometrial cancer. (PubMed id 20082853)^{1, 9} Ghasemi N....Atash-Afza A. (2010)
616. Universal poor survival in children with medulloblast oma harboring somatic TP53 mutations. (PubMed id 20142599)^{1, 9} Tabori U....Hawkins C. (2010)
617. Radiosensitivity profiles from a panel of ovarian can cer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependen t protein kinase activities. (PubMed id 20204287)^{1, 9} Langland G.T....Chen F. (2010)
618. Mutant p53 drives metastasis and overcomes growth arr est/senescence in pancreatic cancer. (PubMed id 20018721)^{1, 9} Morton J.P....Sansom O.J. (2010)
619. p53-mediated induction of Noxa and p53AIP1 requires N FkappaB. (PubMed id 20160496)^{1, 9} O'Prey J....Ryan K.M. (2010)
620. Axin downregulates TCF-4 transcription via beta-caten in, but not p53, and inhibits the proliferation and invasion of lung cancer cel ls. (PubMed id 20122174)^{1, 9} Yang L.H....Wang E.H. (2010)
621. TP53, EGFR, and KRAS mutations in relation to VHL ina ctivation and lifestyle risk factors in renal-cell carcinoma from central and e astern Europe. (PubMed id 20137853)^{1, 9} SzymaA8ska K....Brennan P. (2010)
622. The coordinated p53 and estrogen receptor cis-regulat ion at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic comp ound. (PubMed id 20422012)^{1, 9} Ciribilli Y....Inga A. (2010)
623. A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck. (PubMed id 20142252)^{1, 9} Tandon S....Jones T.M. (2010)
624. Decreased PM10 exposure attenuates age-related lung f unction decline: genetic variants in p53, p21, and CCND1 modify this effect. (PubMed id 19750108)^{1, 9} Imboden M....Probst-Hensch N.M. (2009)
625. Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/ beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma. (PubMed id 19608668)^{1, 9} Boulanger E....Pineau P. (2009)
626. Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide. (PubMed id 19305157)^{1, 9} Sato Y....Sawai T. (2009)
627. Aneuploidy is associated with TP53 expression but not with BRCA1 or TERT expression in sporadic colorectal cancer. (PubMed id 20032382)^{1, 9} SchjA...De Angelis P.M. (2009)
628. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. (PubMed id 19366810)^{1, 9} Yokobori T....Mori M. (2009)
629. The combined status of ATM and p53 link tumor develop ment with therapeutic response. (PubMed id 19608766)^{1, 9} Jiang H....Hemann M.T. (2009)
630. Mutational spectrum of conserved regions of TP53 and PTEN genes in Kangri cancer (of the skin) in the Kashmiri population. (PubMed id 19486858)^{1, 9} Hussain I....Siddiqi M.A. (2009)
631. Association of TP53 and MDM2 polymorphisms with survi val in bladder cancer patients treated with chemoradiotherapy. (PubMed id 19764997)^{1, 9} Shinohara A....Matsuyama H. (2009)
632. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. (PubMed id 19357867)^{1, 9} Dai S....Cheng H. (2009)
633. Differential protein immunoexpression profiles in app endiceal mucinous neoplasms: a special reference to classification and predicti ve factors. (PubMed id 19448592)^{1, 9} Yoon S.O....Chang M.S. (2009)
634. Association between MGMT promoter hypermethylation an d p53 mutation in glioblastoma. (PubMed id 19544111)^{1, 9} Shamsara J....Behravan J. (2009)
635. KLF4 suppresses estrogen-dependent breast cancer grow th by inhibiting the transcriptional activity of ERalpha. (PubMed id 19503094)^{1, 9} Akaogi K....Yanagisawa J. (2009)
636. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutation s in World Health Organization grade II gliomas. (PubMed id 19816195)^{1, 9} Thon N....Kreth F.W. (2009)
637. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. (PubMed id 19171829)^{1, 9} El Hallani S....Sanson M. (2009)
638. Expression of p53, p16INK4A, pRb, p21WAF1/CIP1, p27KI P1, cyclin D1, Ki-67 and HPV DNA in sinonasal endophytic Schneiderian (inverted ) papilloma. (PubMed id 19863319)^{1, 9} Altavilla G....Marioni G. (2009)
639. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. (PubMed id 19247656)^{1, 9} Huang Z.H....Du X. (2009)
640. Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with cli nicopathological parameters of tumors. (PubMed id 20009884)^{1, 9} Bar J.K....GryboA9 M. (2009)
641. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. (PubMed id 19386249)^{1, 9} De Feo E....Boccia S. (2009)
642. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. (PubMed id 19234440)^{1, 9} Inamura K....Ishikawa Y. (2009)
643. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. (PubMed id 18989634)^{1, 9} Figueroa J.D....Chow W.H. (2009)
644. A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: Evidence from 15,857 subjects. (PubMed id 19178978)^{1, 9} Li Y....Song Y. (2009)
645. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. (PubMed id 19239324)^{1, 9} Cao Z....Park W.S. (2009)
646. Expression of p53, VEGF, microvessel density, and cyc lin-D1 in noncancerous tissue of inflammatory bowel disease. (PubMed id 19034659)^{1, 9} Alkim C....Sahin B. (2009)
647. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. (PubMed id 19234438)^{1, 9} Catasus L....Prat J. (2009)
648. Correlation between angiogenesis and p53 expression in lung adenocarcinoma of young patients. (PubMed id 19212102)^{1, 9} Kondou M....Iwasaki K. (2009)
649. Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells. (PubMed id 19026165)^{1, 9} Zhuang Z.G....Jin W. (2008)
650. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. (PubMed id 18379354)^{1, 9} Ludovini V....Tonato M. (2008)
651. Polymorphism of XRCC1 and the frequency of mutation in codon 249 of the p53 gene in hepatocellular carcinoma among Guangxi population, China. (PubMed id 17849423)^{1, 9} Long X.D....Lu Y.L. (2008)
652. Presence of simian virus 40 in diffuse large B-cell lymphomas in Tunisia correlates with germinal center B-cell immunophenotype, t(14;18) translocation, and P53 accumulation. (PubMed id 18165800)^{1, 9} Amara K....Korbi S. (2008)
653. Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of p53, NF-Y, and p38 mitogen-activated protein kinase. (PubMed id 18541673)^{1, 9} Lecona E....Lizarbe M.A. (2008)
654. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. (PubMed id 19138991)^{1, 9} Tang Y....Zi X. (2008)
655. P53 and bcl-2 assessment in serous ovarian carcinoma. (PubMed id 18334006)^{1, 9} Palmer J.E....Rollason T.P. (2008)
656. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. (PubMed id 18559494)^{1, 9} Abedini M.R....Tsang B.K. (2008)
657. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. (PubMed id 18402691)^{1, 9} Cavallone L....Tonin P.N. (2008)
658. KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. (PubMed id 19020536)^{1, 9} Agell L....Lloreta J. (2008)
659. p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells. (PubMed id 18267949)^{1, 9} Bhana S....Lloyd D.R. (2008)
660. [Clinical significance of the expression of p53, p63 and p73 in nasal and paranasal sinus carcinoma] (PubMed id 19119599)^{1, 9} Zhang T....Tang Z. (2008)
661. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. (PubMed id 18202704)^{1, 9} Weinmann L....Weller M. (2008)
662. Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes. (PubMed id 18386458)^{1, 9} Kalogiannidis I....Makedos G. (2008)
663. TP53 gene mutations as an independent marker for urinary bladder cancer progression. (PubMed id 18425359)^{1, 9} Ecke T.H....Schlechte H.H. (2008)
664. p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. (PubMed id 19033390)^{1, 9} Karni-Schmidt O....Prives C. (2008)
665. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. (PubMed id 17541742)^{1, 9} Arcand S.L....Tonin P.N. (2008)
666. Focal cortical dysplasia type II (malformations of cortical development) aberrantly expresses apoptotic proteins. (PubMed id 18594472)^{1, 9} Chamberlain W.A. and Prayson R.A. (2008)
667. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. (PubMed id 18646041)^{1, 9} Tseng P.L....Hu T.H. (2008)
668. Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients. (PubMed id 19072763)^{1, 9} Gao W....Keohavong P. (2008)
669. Class I phosphatidylinositol 3-kinase inhibitor LY294002 activates autophagy and induces apoptosis through p53 pathway in gastric cancer cell line SGC7901. (PubMed id 18330473)^{1, 9} Xing C....Zhang L. (2008)
670. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. (PubMed id 18988302)^{1, 9} Zhu Z.Z....Zhu G.S. (2008)
671. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. (PubMed id 18701437)^{1, 9} Chen X....Li G. (2008)
672. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. (PubMed id 18310316)^{1, 9} Avery-Kiejda K.A....Hersey P. (2008)
673. p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases. (PubMed id 18803266)^{1, 9} Chen R.H....Tsai F.J. (2008)
674. Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma. (PubMed id 18425390)^{1, 9} Fujiwara K....Umesaki N. (2008)
675. Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53. (PubMed id 18391982)^{1, 9} Matsui Y....Nishiyama H. (2008)
676. 15-deoxy-Delta(12,14)-prostaglandin J2 induces vascular endothelial cell apoptosis through the sequential activation of MAPKS and p53. (PubMed id 18718914)^{1, 9} Ho T.C....Tsao Y.P. (2008)
677. [Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer] (PubMed id 18393238)^{1, 9} Wang A.Z....Cong W.M. (2008)
678. Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis. (PubMed id 18372914)^{1, 9} Tseng R.C....Wang Y.C. (2008)
679. Mutations in the Nijmegen breakage syndrome gene in medulloblastomas. (PubMed id 18593981)^{1, 9} Huang J....Ohgaki H. (2008)
680. An increased lung cancer risk associated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran. (PubMed id 17208332)^{1, 9} Nadji S.A....Mokhtari-Azad T. (2007)
681. Regulation of H-ras splice variant expression by cross talk between the p53 and nonsense-mediated mRNA decay pathways. (PubMed id 17709397)^{1, 9} Barbier J....Auboeuf D. (2007)
682. Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade. (PubMed id 17536310)^{1, 9} Sabah M....Kay E. (2007)
683. Missense mutation with/without nonsense mutation of the p53 gene is associated with large cell morphology in human malignant lymphoma. (PubMed id 17587242)^{1, 9} Mitani S....Mori S. (2007)
684. [Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma] (PubMed id 18330257)^{1, 9} Li Q....Peng P. (2007)
685. Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers. (PubMed id 17280505)^{1, 9} Huang C.L....Miyatake A. (2007)
686. Absence of p53 enhances growth defects and etoposide sensitivity of human cells lacking the Bloom syndrome helicase BLM. (PubMed id 17630856)^{1, 9} So S....Koyama H. (2007)
687. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. (PubMed id 17504383)^{1, 9} Athanassiadou P....Patsouris E. (2007)
688. Gene expression of cyclin-dependent kinase subunit Cks2 is repressed by the tumor suppressor p53 but not by the related proteins p63 or p73. (PubMed id 17336302)^{1, 9} Rother K....Engeland K. (2007)
689. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. (PubMed id 17428325)^{1, 9} Baynes C....Dunning A.M. (2007)
690. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. (PubMed id 16996204)^{1, 9} Eachkoti R....Siddiqi M.A. (2007)
691. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. (PubMed id 17546594)^{1, 9} Zhou Y....Wu X.T. (2007)
692. Expression of p53 in colorectal carcinoma: correlation with clinicopathologic features. (PubMed id 17198452)^{1, 9} Ghavam-Nasiri M.R....Malekifard H. (2007)
693. Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population. (PubMed id 17079356)^{1, 9} Mitra S....Roychoudhury S. (2007)
694. [Study on the relationship between the polymorphism of p53 gene intron 7 and non-small cell lung cancer (NSCLC) and p53 mutation in NSCLC tissues] (PubMed id 17557246)^{1, 9} Gu Q.H....Yang H.Z. (2007)
695. P53 mutations in urinary bladder cancer patients from Central Poland. (PubMed id 17495352)^{1, 9} Borkowska E....Kal/uzewski B. (2007)
696. P53 gene mutations in surgical margins and primary tumor tissues of patients with squamous cell carcinoma of the head and neck. (PubMed id 17557566)^{1, 9} Tunca B....Egeli U. (2007)
697. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. (PubMed id 18089819)^{1, 9} Batista L.F....Kaina B. (2007)
698. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. (PubMed id 18006764)^{1, 9} Huang S.P....Wu M.T. (2007)
699. Molecular basis for the inhibition of p53 by Mdmx. (PubMed id 17938582)^{1, 9} Popowicz G.M....Holak T.A. (2007)
700. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. (PubMed id 17341484)^{1, 9} Johnson N....Peto J. (2007)
701. p53 genetic abnormalities and P-glycoprotein expression in stump and primary gastric carcinomas. (PubMed id 17523278)^{1, 9} Oliver I....Calpena R. (2007)
702. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. (PubMed id 17912468)^{1, 9} Sousa H....Medeiros R. (2007)
703. Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer. (PubMed id 16448675)^{1, 9} Samowitz W.S....Slattery M.L. (2006)
704. Genetic status of p53 in stomach cancer: somatic mutations and polymorphism of codon 72. (PubMed id 16984108)^{1, 9} Belyavskaya V.A....Voevoda M.I. (2006)
705. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines. (PubMed id 16941491)^{1, 9} Zheng L....Liu W. (2006)
706. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo. (PubMed id 16969499)^{1, 9} Quaresima B....Venuta S. (2006)
707. Human papillomavirus and p53 polymorphism in Lithuanian cervical cancer patients. (PubMed id 16488468)^{1, 9} Gudleviciene Z....Valuckas K.P. (2006)
708. Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. (PubMed id 16963839)^{1, 9} Choi W....Zhang W. (2006)
709. Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters. (PubMed id 17012841)^{1, 9} Lee J.J....Heo D.S. (2006)
710. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. (PubMed id 17000754)^{1, 9} Bartz S.R....Linsley P.S. (2006)
711. AP-2alpha and AP-2gamma are transcriptional targets of p53 in human breast carcinoma cells. (PubMed id 16636674)^{1, 9} Li H....Domann F.E. (2006)
712. Oncogenes and the DNA damage response: Myc and E2F1 engage the ATM signaling pathway to activate p53 and induce apoptosis. (PubMed id 16582589)^{1, 9} Hong S....Johnson D.G. (2006)
713. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. (PubMed id 16652373)^{1, 9} Stern M.C....Taylor J.A. (2006)
714. A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. (PubMed id 17072987)^{1, 9} Yi S.Y. and Lee W.J. (2006)
715. [P53 codon 72 polymorphism in cervical cancers and its correlation with HPV16,18E6] (PubMed id 16761419)^{1, 9} Hou M.M....Sun Z.L. (2006)
716. Mutations in exons 6 and 7 of TP53 gene correlate positively with serum tumor necrosis factor alpha independent of microsatellite instability in BAT26 gene in Egyptian patients with endometrial carcinoma. (PubMed id 17013801)^{1, 9} Diab A.M....Elsammak M. (2006)
717. Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells. (PubMed id 16616141)^{1, 9} Panno M.L....Ando S. (2006)
718. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. (PubMed id 16552814)^{1, 9} Perez L.O....Golijow C.D. (2006)
719. Inactivation of the p53 pathway in retinoblastoma. (PubMed id 17080083)^{1, 9} Laurie N.A....Dyer M.A. (2006)
720. Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. (PubMed id 17050687)^{1, 9} Agarwal M.K....Agarwal M.L. (2006)
721. Different p53 mutation patterns in colorectal tumors from smokers and nonsmokers. (PubMed id 16721749)^{1, 9} Huang C.C....Lee H. (2006)
722. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. (PubMed id 16808798)^{1, 9} Wu X....Jiang W.J. (2006)
723. Novel P53 mutations detected by FAMA in colorectal cancers. (PubMed id 16760300)^{1, 9} De Galitiis F....Ricevuto E. (2006)
724. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. (PubMed id 16847267)^{1, 9} Monte M....Schneider C. (2006)
725. Upper aerodigestive tract squamous dysplasia: correlation with p16, p53, pRb, and Ki-67 expression. (PubMed id 16948516)^{1, 9} Wayne S. and Robinson R.A. (2006)
726. The p53 pathway and outcome among patients with T1G3 bladder tumors. (PubMed id 17062677)^{1, 9} Lopez-Knowles E....Real F.X. (2006)
727. Association of p53 Arg72Pro polymorphism and beta-catenin accumulation in mycosis fungoides. (PubMed id 17107393)^{1, 9} Bellei B....Picardo M. (2006)
728. Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. (PubMed id 15964795)^{1, 9} Berger M....Haupt Y. (2005)
729. The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. (PubMed id 16024113)^{1, 9} Eriksen J.G....Overgaard J. (2005)
730. TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor. (PubMed id 15578720)^{1, 9} Spiesbach K....Engeland K. (2005)
731. p38 MAP kinase regulates benzo(a)pyrene-induced apoptosis through the regulation of p53 activation. (PubMed id 16297369)^{1, 9} Kim S.J....Park R. (2005)
732. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. (PubMed id 16077963)^{1, 9} Matsuhashi N....Saji S. (2005)
733. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. (PubMed id 16007163)^{1, 9} Jeong S.J....Brady J.N. (2005)
734. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. (PubMed id 15814626)^{1, 9} Hu Y....Ahrendt S.A. (2005)
735. Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line. (PubMed id 15550400)^{1, 9} Liu X.H....Levine A.C. (2005)
736. p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53. (PubMed id 15674351)^{1, 9} Curtin J.C. and Spinella M.J. (2005)
737. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B. (PubMed id 15819981)^{1, 9} Soto J.L....Lopez-Nevot M.A. (2005)
738. p53 mutations are common in human papillomavirus type 38-positive non-melanoma skin cancers. (PubMed id 15145527)^{1, 9} Caldeira S....Tommasino M. (2004)
739. Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. (PubMed id 15256449)^{1, 9} Kawamura K....Fukasawa K. (2004)
740. Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis. (PubMed id 14978302)^{1, 9} Ekblad C.M....Itzhaki L.S. (2004)
741. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. (PubMed id 15456784)^{1, 9} Kuo P.C....Chao J.I. (2004)
742. p53-Independent ceramide formation in human glioma cells during gamma-radiation-induced apoptosis. (PubMed id 15088070)^{1, 9} Hara S....Sakai N. (2004)
743. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. (PubMed id 14623878)^{1, 9} Ruiz de Almodovar C....Lopez-Rivas A. (2004)
744. PKCdelta requires p53 for suppression of the transformed phenotype in human colon cancer cells. (PubMed id 15601585)^{1, 9} Perletti G....de Eguileor M. (2004)
745. Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: a preliminary study. (PubMed id 15764300)^{1, 9} Chen Y.C....Christiani D.C. (2004)
746. Mutant p53 protein in the serum of patients with cervical carcinoma: correlation with the level of serum epidermal growth factor receptor and prognostic significance. (PubMed id 14670624)^{4, 9} Oh M.J....Saw H.S. (2004)
747. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. (PubMed id 14737103)^{1, 9} Gao J....Wu X.R. (2004)
748. [Research of fibronectin, p53 and Ezrin protein with occurrence, progress and prognosis in the primary laryngeal carcinoma by the tissuechip technology] (PubMed id 15835821)^{1, 9} Dong P....Zhu J.C. (2004)
749. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. (PubMed id 12958068)^{1, 9} Stankovic T....Taylor A.M. (2004)
750. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. (PubMed id 15263792)^{1, 9} Wu H.C....Chen W.C. (2004)
751. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2. (PubMed id 14640983)^{1, 9} Pospisilova S....Vojtesek B. (2004)
752. The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship? (PubMed id 15557758)^{1, 9} Hussein M.R. (2004)
753. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. (PubMed id 15140942)^{1, 9} Powers J.T....Johnson D.G. (2004)
754. Hsp90 chaperones wild-type p53 tumor suppressor protein. (PubMed id 15358769)^{1, 9} Walerych D....Zylicz M. (2004)
755. Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. (PubMed id 12779080)^{1, 9} Concin N....Zeillinger R. (2003)
756. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients. (PubMed id 14689061)^{1, 9} Klobusicka M....Babusikova O. (2003)
757. Correlation between p53 mutations and HPV in bilharzial bladder cancer. (PubMed id 14670539)^{1, 9} Khaled H.M....Mokhtar N. (2003)
758. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. (PubMed id 12574499)^{1, 9} Yu J....Zhang L. (2003)
759. P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of bladder. (PubMed id 12926093)^{1, 9} Shiraishi K....Kamiryo Y. (2003)
760. The impact of p53 protein core domain structural alteration on ovarian cancer survival. (PubMed id 14519637)^{1, 9} Rose S.L....Buller R.E. (2003)
761. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. (PubMed id 12499093)^{1, 9} Gregorc V....Tonato M. (2003)
762. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response. (PubMed id 12640129)^{1, 9} Lyakhovich A. and Shekhar M.P. (2003)
763. Recognition of DNA modified by antitumor cisplatin by 'latent' and 'active' protein p53. (PubMed id 12694871)^{1, 9} Fojta M....Brabec V. (2003)
764. [Co-detection of P21, P53 and HSP70 and their possible role in diagnosis of polycyclic aromatic hydrocarbons (PAHs)-related lung cancer] (PubMed id 14761400)^{1, 9} Lu Q.F....Wu T.C. (2003)
765. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. (PubMed id 12771886)^{1, 9} Casson A.G....Hainaut P. (2003)
766. TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. (PubMed id 14673037)^{1, 9} Nichols K.E....Diller L. (2003)
767. Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma. (PubMed id 12532420)^{1, 9} Fricke E....Luber B. (2003)
768. Mad2 and p53 expression profiles in colorectal cancer and its clinical significance. (PubMed id 12970887)^{1, 9} Li G.Q....Zhang H.F. (2003)
769. Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells. (PubMed id 12788915)^{1, 9} Ruiz-Ruiz C....Lopez-Rivas A. (2003)
770. Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine. (PubMed id 14623330)^{1, 9} de la Fuente M.T....Garcia-Pardo A. (2003)
771. Genotyping of p53 codon 175 in colorectal cancer. (PubMed id 12761448)^{1, 9} Krajewska W.M....Kilianska Z.M. (2003)
772. p53 gene mutations are rare in human papillomavirus-associated colon cancer. (PubMed id 14534749)^{1, 9} Buyru N....Dalay N. (2003)
773. Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status. (PubMed id 14714296)^{1, 9} Lee J.S....Park C.S. (2003)
774. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. (PubMed id 12884349)^{4, 9} Bradford C.R....Carey T.E. (2003)
775. Human papillomavirus, p53 and cyclin D1 expression in oropharyngeal carcinoma. (PubMed id 14759115)^{1, 9} Kumar R.V....Shah K.V. (2003)
776. Mutation analysis of BrCA1, BrCA2, and p53 versus soluble HLA class I and class II in a case of familial endometriosis. (PubMed id 12568865)^{1, 9} Goumenou A.G....Koutsilieris M. (2003)
777. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. (PubMed id 12101184)^{1, 9} Elmore L.W....Holt S.E. (2002)
778. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. (PubMed id 11739724)^{1, 9} Hsieh J.K....Lu X. (2002)
779. Comparative study in the expression of p53, EGFR, TGF-alpha, and cyclin D1 in verrucous carcinoma, verrucous hyperplasia, and squamous cell carcinoma of head and neck region. (PubMed id 12607604)^{1, 9} Wu M....Bhuiya T.A. (2002)
780. p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. (PubMed id 11983757)^{1, 9} Wu X....Spitz M.R. (2002)
781. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. (PubMed id 11875057)^{1, 9} Saito S....Anderson C.W. (2002)
782. Histopathological study of intraductal papillary mucinous tumor of the pancreas: special reference to the roles of Survivin and p53 in tumorigenesis of IPMT. (PubMed id 12794243)^{1, 9} Jinfeng M....Hirai I. (2002)
783. Neoangiogenesis in colon cancer: correlation between vascular density, vascular endothelial growth factor (VEGF) and p53 protein expression. (PubMed id 11956638)^{1, 9} Faviana P....Fontanini G. (2002)
784. Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families. (PubMed id 12505256)^{1, 9} Balz V....Bojar H. (2002)
785. The diversity of p53 mutations among human brain tumors and their functional consequences. (PubMed id 11900859)^{1, 9} Zupanska A. and Kaminska B. (2002)
786. Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women. (PubMed id 12445252)^{1, 9} Arbel-Alon S....Friedman E. (2002)
787. p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. (PubMed id 12479364)^{1, 9} Cui H....Ding H.F. (2002)
788. Efficient repair of bulky anti-BPDE DNA adducts from non-transcribed DNA strand requires functional p53 but not p21(waf1/cip1) and pRb. (PubMed id 12175902)^{1, 9} Wani M.A....Wani A.A. (2002)
789. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. (PubMed id 12379854)^{1, 9} Kurose K....Eng C. (2002)
790. P53 mediates ceramide-induced apoptosis in SKN-SH cells. (PubMed id 11960374)^{1, 9} Kim S.S....Suh Y.H. (2002)
791. [Alternations of p53 gene, microsatellite instability and proliferation associated antigen Ki-67 in the synchronous multiple colorectal cancers] (PubMed id 11729653)^{4, 9} Asakawa H....Ikegami M. (2001)
792. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. (PubMed id 11597128)^{1, 9} Xirodimas D.P....Lane D.P. (2001)
793. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. (PubMed id 11692157)^{1, 9} Volkmann M....Hofmann W.J. (2001)
794. Association between CagA+ Helicobacter pylori infection and p53, bax and transforming growth factor-beta-RII gene mutations in gastric cancer patients. (PubMed id 11251969)^{1, 9} Deguchi R....Miwa T. (2001)
795. [p53 and vascular endothelial growth factor expression in astrocytoma and their relation to angiogenesis] (PubMed id 11783119)^{1, 9} Ye S....Chen Y. (2001)
796. Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index. (PubMed id 11751402)^{1, 9} Wilson J.W....Norton J.D. (2001)
797. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. (PubMed id 11751390)^{1, 9} Liu G....Christiani D.C. (2001)
798. The p53 codon 72 polymorphism and lung cancer risk. (PubMed id 11045785)^{1, 9} Fan R....Christiani D.C. (2000)
799. Overexpression of p53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5-9. (PubMed id 10862014)^{4, 9} Lingen M.W....Pelzer H.J. (2000)
800. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. (PubMed id 10570149)^{2, 9} Chehab N.H....Halazonetis T.D. (1999)
801. Association of p53 accumulation with TP53 mutations, loss of heterozygosity at 17p13, and DNA ploidy status in 273 colorectal carcinomas. (PubMed id 9917132)^{4, 9} Clausen O.P....Meling G.I. (1998)
802. Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. (PubMed id 9652798)^{4, 9} Tagawa M....Kimura H. (1998)
803. MDMX: a novel p53-binding protein with some functional properties of MDM2. (PubMed id 8895579)^{1, 9} Shvarts A....Jochemsen A.G. (1996)
804. Accumulation of p53 is associated with tumour progression in cutaneous lesions of renal allograft recipients. (PubMed id 7917913)^{4, 9} Stark L.A....Bird C.C. (1994)
805. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. (PubMed id 1565143)^{1, 9} Toguchida J....Sasaki M.S. (1992)
806. Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favo rs apoptosis. (PubMed id 20019240)^{1, 9} Jeong B.S....Levine A.J. (2010)
807. Transcriptional signature of human macrophages expose d to the environmental contaminant benzo(a)pyrene. (PubMed id 20064835)^{1, 9} Sparfel L....Fardel O. (2010)
808. TP53, MDM2, NQO1, and susceptibility to cervical canc er. (PubMed id 20200430)^{1, 9} Hu X....Rader J.S. (2010)
809. PTEN/pAkt/p53 signaling pathway correlates with the r adioresponse of non-small cell lung cancer. (PubMed id 20198299)^{1, 9} Jung I.L....Kim I.G. (2010)
810. RUNX3 modulates DNA damage-mediated phosphorylation o f tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. (PubMed id 20353948)^{1, 9} Yamada C....Nakagawara A. (2010)
811. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemoth erapy. (PubMed id 19806450)^{1, 9} Kim H.S....Ahn S.H. (2010)
812. Frequency and clinical relevance of DNA microsatellit e alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pedi atric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia . (PubMed id 19586936)^{1, 9} Krieger D....Burkhardt B. (2010)
813. p53 overexpression in morphologically ambiguous endom etrial carcinomas correlates with adverse clinical outcomes. (PubMed id 19855378)^{1, 9} Garg K....Soslow R.A. (2010)
814. Mdm2 Snp309 G allele displays high frequency and inve rse correlation with somatic P53 mutations in hepatocellular carcinoma. (PubMed id 19954744)^{1, 9} Acun T....Yakicier M.C. (2010)
815. Associations of MDM2 SNP309, transcriptional activity , mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. (PubMed id 19941079)^{1, 9} Chien W.P....Lee H. (2010)
816. Implication of necrosis-linked p53 aggregation in acq uired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids. (PubMed id 20514446)^{1, 9} Lee S.Y....Kang H.S. (2010)
817. [P53 abnormality and clinical prognosis of leukemia p atients with complex chromosomal abnormalities] (PubMed id 20140875)^{1, 9} Zou Z....Wang Z. (2010)
818. TP53 mutations and pathologic complete response to ne oadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squam ous cell carcinoma. (PubMed id 20048189)^{1, 9} Perrone F....Licitra L. (2010)
819. Association between TP53 gene ARG72PRO polymorphism a nd chromosome aberrations in human cancers. (PubMed id 20512840)^{1, 9} Litviakov N.V....Koshel A.P. (2010)
820. Reactivation of p53 by novel MDM2 inhibitors: implica tions for pancreatic cancer therapy. (PubMed id 20370686)^{1, 9} Azmi A.S....Mohammad R.M. (2010)
821. High frequency of de novo mutations in Li-Fraumeni sy ndrome. (PubMed id 19556618)^{1, 9} Gonzalez K.D....Sommer S.S. (2009)
822. Organophosphorous pesticides and estrogen induce tran sformation of breast cells affecting p53 and c-Ha-ras genes. (PubMed id 19787260)^{1, 9} Calaf G.M....Roy D. (2009)
823. Correlation and expression of COX-2 and P53 protein i n basal cell carcinoma of eyelid. (PubMed id 19513627)^{1, 9} Chen Z....Huang Q. (2009)
824. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. (PubMed id 19783986)^{1, 9} Fontemaggi G....Blandino G. (2009)
825. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. (PubMed id 19672255)^{1, 9} Chua W....Iacopetta B. (2009)
826. Identification of colorectal cancer patients with tum ors carrying the TP53 mutation on the codon 72 proline allele that benefited mo st from 5-fluorouracil (5-FU) based postoperative chemotherapy. (PubMed id 19954513)^{1, 9} Godai T.I....Miyagi Y. (2009)
827. Ethnic differences and functional analysis of MET mut ations in lung cancer. (PubMed id 19723643)^{1, 9} Krishnaswamy S....Salgia R. (2009)
828. Two-round coamplification at lower denaturation tempe rature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of lo w-level mutations in lung adenocarcinoma. (PubMed id 19760750)^{1, 9} Li J....Makrigiorgos G.M. (2009)
829. Expressions of p53, cyclinD1 and histopathological fe atures in basal cell carcinomas. (PubMed id 19187116)^{1, 9} Koseoglu R.D....Etikan I. (2009)
830. Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors. (PubMed id 19224462)^{1, 9} Almeida L.O....Casartelli C. (2009)
831. Activation of NFAT signal by p53-K120R mutant. (PubMed id 19416725)^{1, 9} Shinmen N....Hiwasa T. (2009)
832. Distinct HIC1-SIRT1-p53 loop deregulation in lung squ amous carcinoma and adenocarcinoma patients. (PubMed id 19649206)^{1, 9} Tseng R.C....Wang Y.C. (2009)
833. p53 inhibition of AP1-dependent TFF2 expression induc es apoptosis and inhibits cell migration in gastric cancer cells. (PubMed id 19541923)^{1, 9} Tu S.P....Wang T.C. (2009)
834. Allelic loss of the PTEN gene and mutation of the TP5 3 gene in choriocarcinoma arising from gastric adenocarcinoma: analysis of loss of heterozygosity in two male patients with extragonadal choriocarcinoma. (PubMed id 19665071)^{1, 9} Tate G....Mitsuya T. (2009)
835. Atypical leiomyomas of the uterus with long-term foll ow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki- 67, estrogen receptors, and progesterone receptors. (PubMed id 19851199)^{1, 9} Sung C.O....Bae D.S. (2009)
836. Analysis of mutations in TP53, APC, K-ras, and DCC ge nes in the non-dysplastic mucosa of patients with inflammatory bowel disease. (PubMed id 19543899)^{1, 9} Rapozo D.C....Pinto L.F. (2009)
837. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations. (PubMed id 19602465)^{1, 9} Finkova A....Sedlacek Z. (2009)
838. An insight into the mechanistic role of p53-mediated autophagy induction in response to proteasomal inhibition-induced neurotoxicity . (PubMed id 19337030)^{1, 9} Du Y....Le W. (2009)
839. p53 protein expression in skin with different levels of photoaging. (PubMed id 19292788)^{1, 9} de Castro I.A....Bakos L. (2009)
840. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. (PubMed id 18706692)^{1, 9} Zainuddin N....Enblad G. (2009)
841. Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. (PubMed id 19157504)^{1, 9} Jeong I.G....Lee E. (2009)
842. TP53 codon 72 polymorphism and cervical cancer: a poo led analysis of individual data from 49 studies. (PubMed id 19625214)^{1, 9} Klug S.J....Blettner M. (2009)
843. Detection of gene copy number aberrations in mantle c ell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value. (PubMed id 19594747)^{1, 9} Jardin F....Tilly H. (2009)
844. p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li-Fraumeni syndrome and a child with adrenocortical carcinoma. (PubMed id 19714490)^{1, 9} Fiszer-Maliszewska L....Padzik J. (2009)
845. The apoptotic paradox in retinoblastoma. (PubMed id 19723039)^{1, 9} Sitorus R.S....van der Valk P. (2009)
846. Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women. (PubMed id 19430562)^{1, 9} Cho Y.H....Kim Y.T. (2009)
847. Polymorphisms in HPV E6/E7 protein interacted genes a nd risk of cervical cancer in Chinese women: a case-control analysis. (PubMed id 19482343)^{1, 9} Zhou X....Shen H. (2009)
848. Triptolide induces apoptosis in human anaplastic thyr oid carcinoma cells by a p53-independent but NF-kappaB-related mechanism. (PubMed id 19885592)^{1, 9} Zhu W....Yan G. (2009)
849. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. (PubMed id 19423162)^{1, 9} Xiong X....Wang J. (2009)
850. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. (PubMed id 18996371)^{1, 9} Puca R....D'Orazi G. (2009)
851. Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma. (PubMed id 19666408)^{1, 9} Guo C....Yang X. (2009)
852. Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. (PubMed id 19351845)^{1, 9} Shirley S.H....Fuchs-Young R. (2009)
853. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diff use gliomas of World Health Organization (WHO) grades II and III: a clinicopath ological study. (PubMed id 19019173)^{1, 9} Huang L....Wang Z.C. (2009)
854. ATM-mediated transcriptional elevation of prion in response to copper-induced oxidative stress. (PubMed id 19064990)^{1, 9} Qin K....Zhao R.Y. (2009)
855. Localization of N-myc downstream-regulated gene 1 in gastric cancer tissue. (PubMed id 18602353)^{1, 9} Inagaki Y....Kokudo N. (2009)
856. Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. (PubMed id 19423538)^{1, 9} Koshiol J....Wang S.S. (2009)
857. Identification and characterization of a novel germli ne p53 mutation in a patient with glioblastoma and colon cancer. (PubMed id 19405127)^{1, 9} Yamada H....Sugimura H. (2009)
858. Promoter methylation patterns of ATM, ATR, BRCA1, BRC A2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation car riers. (PubMed id 18642075)^{1, 9} Kontorovich T....Friedman E. (2009)
859. Comparison of the clinical and immunohistochemical fe atures, including anaplastic lymphoma kinase (ALK) and p53, in inflammatory myo fibroblastic tumours. (PubMed id 19589272)^{1, 9} Jiang Y.H....Zhang G. (2009)
860. MSK2 inhibits p53 activity in the absence of stress. (PubMed id 19797274)^{1, 9} Llanos S....Serrano M. (2009)
861. Impaired p53 binding to importin: a novel mechanism o f cytoplasmic sequestration identified in oxaliplatin-resistant cells. (PubMed id 19581934)^{1, 9} Komlodi-Pasztor E....Fojo T. (2009)
862. Detailed analysis of p53 pathway defects in fludarabi ne-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution o f 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. (PubMed id 19643983)^{1, 9} Zenz T....Stilgenbauer S. (2009)
863. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. (PubMed id 19199318)^{1, 9} Lavra L....Sciacchitano S. (2009)
864. Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. (PubMed id 19223905)^{1, 9} Lopergolo A....Zaffaroni N. (2009)
865. Analysis of NQO1 polymorphisms and p53 protein expres sion in patients with hepatocellular carcinoma. (PubMed id 19688691)^{1, 9} Chiu M.M....Chau Y.P. (2009)
866. Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast. (PubMed id 17724467)^{1, 9} Grochova D....Smardova J. (2008)
867. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations. (PubMed id 18469517)^{1, 9} Faridoni-Laurens L....Ahomadegbe J.C. (2008)
868. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. (PubMed id 18281511)^{1, 9} Levesque A.A....Eastman A. (2008)
869. TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. (PubMed id 18230133)^{1, 9} Kupryjanczyk J....Bidzinski M. (2008)
870. Synthetic lethality by lentiviral short hairpin RNA silencing of thymidylate kinase and doxorubicin in colon cancer cells regardless of the p53 status. (PubMed id 18413751)^{1, 9} Hu C.M. and Chang Z.F. (2008)
871. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. (PubMed id 18559976)^{1, 9} Young K.H....Greiner T.C. (2008)
872. Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. (PubMed id 18322661)^{1, 9} Vidaurreta M....Torres A. (2008)
873. Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations. (PubMed id 17962810)^{1, 9} Curia M.C....Battista P. (2008)
874. A newly identified dependence receptor UNC5H4 is induced during DNA damage-mediated apoptosis and transcriptional target of tumor suppressor p53. (PubMed id 18402767)^{1, 9} Wang H....Nakagawara A. (2008)
875. Polypyrimidine tract binding protein regulates IRES-mediated translation of p53 isoforms. (PubMed id 18635961)^{1, 9} Grover R....Das S. (2008)
876. Increased p53 level, Bax/Bcl-x(L) ratio, and TRAIL receptor expression in human emphysema. (PubMed id 18511705)^{1, 9} Morissette M.C....Milot J. (2008)
877. Concomitant presence of mutations in mitochondrial genome and p53 in cancer development - a study in north Indian sporadic breast and esophageal cancer patients. (PubMed id 18792899)^{1, 9} Gochhait S....Bamezai R.N. (2008)
878. Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. (PubMed id 18357466)^{1, 9} Huang Z.H....Zhu J.D. (2008)
879. Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas. (PubMed id 18415123)^{1, 9} Briese J....Bamberger A.M. (2008)
880. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. (PubMed id 18483253)^{1, 9} Puca R....D'Orazi G. (2008)
881. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. (PubMed id 18270270)^{1, 9} Astanehe A....Auersperg N. (2008)
882. Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. (PubMed id 18802408)^{1, 9} Zhao H....Darzynkiewicz Z. (2008)
883. Association between p53 and human papillomavirus in head and neck cancer survival. (PubMed id 18268127)^{1, 9} Smith E.M....Haugen T.H. (2008)
884. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. (PubMed id 19052714)^{1, 9} Kim J.G....Yu W. (2008)
885. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. (PubMed id 18187663)^{1, 9} Carter B.Z....Andreeff M. (2008)
886. TIP30 induces apoptosis under oxidative stress through stabilization of p53 messenger RNA in human hepatocellular carcinoma. (PubMed id 18519672)^{1, 9} Zhao J....Guo Y. (2008)
887. Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers. (PubMed id 18820009)^{1, 9} Hamaguchi M....Yamashita H. (2008)
888. Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53. (PubMed id 18349850)^{1, 9} Szybka M....Rieske P. (2008)
889. p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours. (PubMed id 18781178)^{1, 9} Dimitriadi M....Collins V.P. (2008)
890. Microtubule-associated protein 1B light chain (MAP1B-LC1) negatively regulates the activity of tumor suppressor p53 in neuroblastoma cells. (PubMed id 18656471)^{1, 9} Lee S.Y....Choi K.H. (2008)
891. Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia. (PubMed id 17920683)^{1, 9} Malcikova J....Trbusek M. (2008)
892. Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53. (PubMed id 18497562)^{1, 9} Chan J.Y....Lee S.C. (2008)
893. Role of p53 Codon 72 Arginine Allele in Cell Survival in vitro and in the Clinical Outcome of Patients with Advanced Breast Cancer. (PubMed id 18612219)^{1, 9} Vannini I....Bonafe M. (2008)
894. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations. (PubMed id 18330889)^{1, 9} Mahdavinia M....Mariani-Costantini R. (2008)
895. Proliferation and programmed cell death: role of p53 protein in high and low grade astrocytoma. (PubMed id 18383819)^{1, 9} Facoetti A....Nano R. (2008)
896. Maspin and Mutant p53 expression in malignant melanoma and carcinoma: use of tissue microarray. (PubMed id 18091325)^{1, 9} Webber B.A....Cohen C. (2008)
897. Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma. (PubMed id 17982487)^{1, 9} Stocklein H....Kalla J. (2008)
898. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. (PubMed id 18172257)^{1, 9} Bartel F....Hauptmann S. (2008)
899. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. (PubMed id 17975552)^{1, 9} Dey A....Lane D.P. (2008)
900. Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer. (PubMed id 18555592)^{1, 9} Hassan N.M....Moriuchi T. (2008)
901. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer. (PubMed id 17949449)^{1, 9} Ahmed I.A....Lunec J. (2008)
902. Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. (PubMed id 18510673)^{1, 9} Nan H....Han J. (2008)
903. Cooperative roles of c-Abl and Cdk5 in regulation of p53 in response to oxidative stress. (PubMed id 18490454)^{1, 9} Lee J.H....Kim K.T. (2008)
904. p53 is important for the anti-proliferative effect of ibuprofen in colon carcinoma cells. (PubMed id 18036557)^{1, 9} Janssen A....Grosch S. (2008)
905. ATM and Chk2 kinase target the p53 cofactor Strap. (PubMed id 18833288)^{1, 9} Adams C.J....La Thangue N.B. (2008)
906. Inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) represses the expression of presenilin-1 by a p53-dependent mechanism. (PubMed id 18374905)^{1, 9} Lee S. and Das H.K. (2008)
907. Suppression of Gadd45 alleviates the G2/M blockage and the enhanced phosphorylation of p53 and p38 in zinc supplemented normal human bronchial epithelial cells. (PubMed id 18296737)^{1, 9} Shih R.S....Lei K.Y. (2008)
908. Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. (PubMed id 17917588)^{1, 9} Ren Z.P....Nister M. (2007)
909. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. (PubMed id 17269744)^{1, 9} Puchades M....Conrad C.A. (2007)
910. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia. (PubMed id 17954263)^{1, 9} Hadhri-Guiga B....Mokdad-Gargouri R. (2007)
911. Germ-line genetic variation of TP53 in osteosarcoma. (PubMed id 17096406)^{1, 9} Savage S.A....Chanock S.J. (2007)
912. Ser46 phosphorylation of p53 is not always sufficient to induce apoptosis: multiple mechanisms of regulation of p53-dependent apoptosis. (PubMed id 17584297)^{1, 9} Kurihara A....Ikawa S. (2007)
913. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells. (PubMed id 17252199)^{1, 9} Pratt M.A....Niu M.Y. (2007)
914. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53. (PubMed id 17097318)^{1, 9} Niu J....Han Z. (2007)
915. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. (PubMed id 17684018)^{1, 9} Selvendiran K....Kuppusamy P. (2007)
916. Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas. (PubMed id 17689819)^{1, 9} Valbuena A....Lazo P.A. (2007)
917. TGF-betaRII, BAX, IGFIIR, caspase-5, hMSH3 and hMSH6 alterations are not associated with microsatellite instability or p53 mutations in invasive urothelial carcinoma of the urinary bladder. (PubMed id 17676485)^{1, 9} Saetta A.A....Patsouris E. (2007)
918. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells. (PubMed id 18092951)^{1, 9} Kuncova J....Mandys V. (2007)
919. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. (PubMed id 17369602)^{1, 9} Di Leo A....Isola J. (2007)
920. Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL. (PubMed id 17699158)^{1, 9} Sot B....Fersht A.R. (2007)
921. p53-Dependent p21 mRNA elongation is impaired when DNA replication is stalled. (PubMed id 17158927)^{1, 9} Mattia M....Prives C. (2007)
922. Abrogation of p53 by its antisense in MCF-7 breast carcinoma cells increases cyclin D1 via activation of Akt and promotion of cell proliferation. (PubMed id 17935714)^{1, 9} Chhipa R.R....Bhat M.K. (2007)
923. Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas. (PubMed id 17656254)^{1, 9} Idbaih A....Delattre J.Y. (2007)
924. Involvement of Kruppel-like factor 6 (KLF6) mutation in the development of nonpolypoid colorectal carcinoma. (PubMed id 17663506)^{1, 9} Mukai S....Chayama K. (2007)
925. Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. (PubMed id 17354237)^{1, 9} Baalbergen A....Helmerhorst T.J. (2007)
926. p53 is required for etoposide-induced apoptosis of human embryonic stem cells. (PubMed id 19383392)^{1, 9} Grandela C....Wolvetang E.J. (2007)
927. Correlations in survivin expression with the expression of p53 and bcl-2 in invasive ductal carcinoma of the breast. (PubMed id 18041310)^{1, 9} Al-Joudi F.S....Imran A.K. (2007)
928. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage. (PubMed id 17390010)^{1, 9} Kawamata H....Fujimori T. (2007)
929. Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. (PubMed id 17471233)^{1, 9} Chipoy C....Blanchard F. (2007)
930. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. (PubMed id 17881637)^{1, 9} Young K.H....Greiner T.C. (2007)
931. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. (PubMed id 17659731)^{1, 9} Salek C....Minarik M. (2007)
932. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. (PubMed id 17690688)^{1, 9} Ou Y.H....Shieh S.Y. (2007)
933. Congenital glioblastoma: a clinicopathologic and genetic analysis. (PubMed id 17465990)^{1, 9} Brat D.J....Perry A. (2007)
934. Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma. (PubMed id 18161662)^{1, 9} Mattioni M....Guadagni F. (2007)
935. The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas. (PubMed id 17671118)^{1, 9} Miyasaka Y....Tsuneyoshi M. (2007)
936. Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer. (PubMed id 17490733)^{1, 9} Albitar L....Leslie K.K. (2007)
937. Novel p53/p130 axis in bladder tumors. (PubMed id 17905135)^{1, 9} Mudryj M....Gandour-Edwards R. (2007)
938. [Both somatic and germline genetics of the TP53-pathway influence ovarian cancer incidence and survival] (PubMed id 18314620)^{1, 9} Bohnke A....Bartel F. (2007)
939. Significance of genetic abnormalities of p53 protein in Slovenian patients with gastric carcinoma. (PubMed id 17436385)^{1, 9} Juvan R....Komel R. (2007)
940. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. (PubMed id 18006810)^{1, 9} Cheng Y.W....Lee H. (2007)
941. p53 Gene mutations in sporadic colorectal carcinoma in Guangxi region. (PubMed id 17118779)^{1, 9} Gao F....Tang W. (2006)
942. Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma. (PubMed id 16521213)^{1, 9} Akimoto M....Saisho H. (2006)
943. Regulation of protein synthesis by inducible wild-type p53 in human lung carcinoma cells. (PubMed id 16504179)^{1, 9} Tilleray V....Clemens M.J. (2006)
944. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. (PubMed id 16459017)^{1, 9} Ueno Y....Murata Y. (2006)
945. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. (PubMed id 16912210)^{1, 9} Wu C.C....Strong L.C. (2006)
946. Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never-smokers. (PubMed id 16865671)^{1, 9} Gao W.M....Keohavong P. (2006)
947. p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. (PubMed id 16951143)^{1, 9} Jackson J.G. and Pereira-Smith O.M. (2006)
948. P53 and PCNA immunoexpression in endometrial carcinomas. (PubMed id 17106521)^{1, 9} Simionescu C....Patru E. (2006)
949. p53 Mutation analysis of low-grade dysplasia and high-grade dysplasia/carcinoma in situ of the esophagus using laser capture microdissection. (PubMed id 17652955)^{1, 9} Kobayashi M....Koike M. (2006)
950. Detecting low-abundance p16 and p53 mutations in pancreatic juice using a novel assay: heteroduplex analysis of limiting dilution PCRs. (PubMed id 17106238)^{1, 9} Bian Y....Goggins M. (2006)
951. p53 codon 72 polymorphism in basal cell carcinoma of the skin. (PubMed id 16554913)^{1, 9} Pezeshki A....Doroudchi M. (2006)
952. The p33ING1b tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells. (PubMed id 16325212)^{1, 9} Zhu J.J....Liao W.M. (2006)
953. Germline polymorphism of p53 codon 72 in gynecological cancer. (PubMed id 16168468)^{1, 9} Ueda M....Ueki M. (2006)
954. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. (PubMed id 16328005)^{1, 9} Kunze E....Schlott T. (2006)
955. Specific TP53 mutation pattern in radiation-induced sarcomas. (PubMed id 16492679)^{1, 9} Gonin-Laurent N....Malfoy B. (2006)
956. Mechanistic insights into maintenance of high p53 acetylation by PTEN. (PubMed id 16916644)^{1, 9} Li A.G....Liu X. (2006)
957. Analysis of p53 codon 72 polymorphism and its association with human papillomavirus 16 and 18 E6 in Chinese cervical lesions. (PubMed id 17177838)^{1, 9} Min-min H....Zhi-lin S. (2006)
958. Effects of silencing of mutant p53 gene in human lung adenocarcinoma cell line Anip973. (PubMed id 17310850)^{1, 9} Ma L.L....Fu S.B. (2006)
959. Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. (PubMed id 17374954)^{1, 9} Perfumo C....Varesco L. (2006)
960. Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription. (PubMed id 17018618)^{1, 9} Torosyan Y....Srivastava M. (2006)
961. p53 gene gets altered by various mechanisms: studies in childhood sarcomas and retinoblastoma. (PubMed id 17136003)^{1, 9} Ghule P....Agarwal M. (2006)
962. Antisense p53 decreases production of VEGF in follicular thyroid cancer cells. (PubMed id 16943578)^{1, 9} Hassan I....Zielke A. (2006)
963. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation. (PubMed id 15977174)^{1, 9} Capponcelli S....Sangiorgi L. (2005)
964. Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis. (PubMed id 15940268)^{1, 9} Chaturvedi V....Nickoloff B.J. (2005)
965. p53 intronic G13964C variant in colon cancer and its association with HPV. (PubMed id 16080524)^{1, 9} Buyru N....Dalay N. (2005)
966. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. (PubMed id 15950766)^{1, 9} Parhar P....Newcomb E.W. (2005)
967. The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter. (PubMed id 16351648)^{1, 9} Kamijima S....Ito H. (2005)
968. TP53 mutations in ovarian carcinomas from sporadic ca ses and carriers of two distinct BRCA1 founder mutations; relation to age at di agnosis and survival. (PubMed id 16229746)^{1, 9} Kringen P....Dorum A. (2005)
969. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. (PubMed id 16094360)^{1, 9} Hemann M.T....Lowe S.W. (2005)
970. Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. (PubMed id 15966238)^{1, 9} Lai K.C....Jeng L.B. (2005)
971. p53 mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis. (PubMed id 15386362)^{1, 9} Ito S....Maehara Y. (2005)
972. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. (PubMed id 15943410)^{1, 9} Hsieh J.S....Wang J.Y. (2005)
973. Human papillomavirus genotypes and the p53 codon 72 polymorphism in cervical cancer of Northeastern Thailand. (PubMed id 15905603)^{1, 9} Settheetham-Ishida W....Ishida T. (2005)
974. OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer. (PubMed id 16211227)^{1, 9} Arcand S.L....Tonin P.N. (2005)
975. Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from Northern Brazil with gastric adenocarcinoma. (PubMed id 16362795)^{1, 9} Khayat A.S....Burbano R.R. (2005)
976. Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen- and estrogen-receptor independent. (PubMed id 15752352)^{1, 9} Zapata E....Lopez-Marure R. (2005)
977. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. (PubMed id 15902285)^{1, 9} Davies A.J....Fitzgibbon J. (2005)
978. [Expression of BAG-1 and p53 in laryngeal squamous cell carcinoma and their clinical significance] (PubMed id 16398049)^{1, 9} Wu S....Yin S. (2005)
979. Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species. (PubMed id 15705792)^{1, 9} Karawajew L....Ludwig W.D. (2005)
980. p21(Waf1/Cip1) and p53 are downstream effectors of protein kinase C delta in tumor suppression and differentiation in human colon cancer cells. (PubMed id 15386430)^{1, 9} Perletti G....Tashjian A.H. (2005)
981. Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. (PubMed id 16082226)^{1, 9} Zerbini L.F....Libermann T.A. (2005)
982. Effect of Helicobacter pylori infection on p53 expression of gastric mucosa and adenocarcinoma with microsatellite instability. (PubMed id 16038035)^{1, 9} Li J.H....Xu G.W. (2005)
983. The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases. (PubMed id 15713979)^{1, 9} Kapur S....Parwaresch R. (2005)
984. The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. (PubMed id 15933740)^{1, 9} Bar J....Oren M. (2005)
985. Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. (PubMed id 15841715)^{1, 9} Perez-Perez G.I....Garza-Gonzalez E. (2005)
986. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. (PubMed id 15073118)^{1, 9} Wang J.L....Wallin K.L. (2004)
987. The role of p53 codon 72 and human papilloma virus status of cutaneous squamous cell carcinoma in the Swedish population. (PubMed id 15844633)^{1, 9} Gustafsson A.C....Lundeberg J. (2004)
988. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. (PubMed id 15041737)^{1, 9} Boyer J....Johnston P.G. (2004)
989. The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. (PubMed id 15153330)^{1, 9} Watts G.S....Futscher B.W. (2004)
990. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. (PubMed id 15334064)^{1, 9} Zhu N....Zhou M. (2004)
991. p42/44 Mitogen-activated protein kinase regulated by p53 and nitric oxide in human pulmonary arterial smooth muscle cells. (PubMed id 15016620)^{1, 9} Mizuno S....Ishizaki T. (2004)
992. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. (PubMed id 15064416)^{1, 9} Lee J.-H. and Paull T.T. (2004)
993. Expression of survivin, bcl-2, P53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a). (PubMed id 15149158)^{1, 9} Kayaselcuk F....Seydioglu G. (2004)
994. Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans. (PubMed id 14991543)^{1, 9} Takahira T....Tsuneyoshi M. (2004)
995. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. (PubMed id 15183530)^{1, 9} Granja F....Ward L.S. (2004)
996. The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes. (PubMed id 14755251)^{1, 9} Jones G.G....Sherrington P.D. (2004)
997. Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. (PubMed id 15041222)^{1, 9} Cortezzi S.S....Rahal P. (2004)
998. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. (PubMed id 15016801)^{1, 9} Kho P.S....Yu Q. (2004)
999. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. (PubMed id 15047823)^{1, 9} Horner S.M....DiMaio D. (2004)
1000. Upregulation of p16(INK4A) and Bax in p53 wild/p53-overexpressing crypts in ulcerative colitis-associated tumours. (PubMed id 15292938)^{1, 9} Yoshida T....Okayasu I. (2004)
1001. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. (PubMed id 15105048)^{1, 9} Leveri M....Silini E.M. (2004)
1002. Analysis of the codon 72 polymorphism of the TP53 gene in patients with endometriosis. (PubMed id 15273281)^{1, 9} Lattuada D....Di Blasio A.M. (2004)
1003. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. (PubMed id 15471885)^{1, 9} Thompson T....Vassilev L.T. (2004)
1004. Ceramide triggers caspase activation during gamma-radiation-induced apoptosis of human glioma cells lacking functional p53. (PubMed id 15201971)^{1, 9} Hara S....Sakai N. (2004)
1005. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin. (PubMed id 15381368)^{1, 9} Bendig I....Weber B.H. (2004)
1006. P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. (PubMed id 15554555)^{1, 9} Agorastos T....Bontis I. (2004)
1007. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. (PubMed id 14724564)^{1, 9} Roos W....Kaina B. (2004)
1008. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization. (PubMed id 14716820)^{1, 9} Xiao E.H....Huang J.F. (2004)
1009. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. (PubMed id 15099937)^{1, 9} Leitao M.M....Boyd J. (2004)
1010. Ubiquitous p63 expression in human esophageal squamous cell carcinoma. (PubMed id 15254760)^{1, 9} Hara T....Makuuchi H. (2004)
1011. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). (PubMed id 15149599)^{1, 9} Herbig U....Sedivy J.M. (2004)
1012. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas. (PubMed id 14719118)^{1, 9} Cerrato J.A....Liu T.J. (2004)
1013. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. (PubMed id 15351976)^{1, 9} Cavalcanti G.B....Maia R.C. (2004)
1014. Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer. (PubMed id 15350302)^{1, 9} Cesar A.C....Silva A.E. (2004)
1015. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. (PubMed id 12567188)^{1, 9} Dumont P....Murphy M. (2003)
1016. Potential role of MLH1 in the induction of p53 and apoptosis by blocking transcription on damaged DNA templates. (PubMed id 12939400)^{1, 9} Yanamadala S. and Ljungman M. (2003)
1017. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish 'Malova' Ovarian Cancer Study. (PubMed id 12926080)^{1, 9} Hogdall E.V....Hogdall C.K. (2003)
1018. Ethnic variation of the P53 codon 72 polymorphism, HPV persistence, and cervical cancer risk. (PubMed id 14678586)^{1, 9} Inserra P....Giuliano A.R. (2003)
1019. Dephosphorylation of p53 during cell death by N-alpha-tosyl-L-phenylalanyl chloromethyl ketone. (PubMed id 12821135)^{1, 9} Kim K....Joe C.O. (2003)
1020. p53 expression in oral cancer: observations of a South Indian study. (PubMed id 14582705)^{1, 9} Pillay M....Vidya M. (2003)
1021. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. (PubMed id 12524540)^{1, 9} Bergamaschi D.... Lu X. (2003)
1022. Somatic mutation analysis of p53 and ST7 tumor suppressor genes in gastric carcinoma by DHPLC. (PubMed id 14669308)^{1, 9} Lu C....Zhang X. (2003)
1023. A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas. (PubMed id 13678722)^{1, 9} Koyamatsu Y....Iwasaka T. (2003)
1024. Simulated sunlight and benzo[a]pyrene diol epoxide induced mutagenesis in the human p53 gene evaluated by the yeast functional assay: lack of correspondence to tumor mutation spectra. (PubMed id 12538356)^{1, 9} Yoon J.H....Pfeifer G.P. (2003)
1025. Conjugated linoleic acid inhibits cell proliferation through a p53-dependent mechanism: effects on the expression of G1-restriction points in breast and colon cancer cells. (PubMed id 14608092)^{1, 9} Kemp M.Q....Romagnolo D.F. (2003)
1026. BRCA1 and p53: compensatory roles in DNA repair. (PubMed id 13679996)^{1, 9} Hartman A.R. and Ford J.M. (2003)
1027. Cytoplasmic complex of p53 and eEF2. (PubMed id 12891704)^{1, 9} Yin X....Carroll R.B. (2003)
1028. A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors. (PubMed id 12885464)^{4, 9} Trkova M....Sedlacek Z. (2003)
1029. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. (PubMed id 12901974)^{1, 9} Narendran A....Freedman M.H. (2003)
1030. Telomerase in relation to expression of p53, c-Myc and estrogen receptor in ovarian tumours. (PubMed id 14532990)^{1, 9} Wisman G.B....Van der Zee A.G. (2003)
1031. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. (PubMed id 12569576)^{1, 9} Narayanan B.A....Nixon D.W. (2003)
1032. Evaluation of metallothionein and p53 expression as potential prognostic markers for laryngeal squamous cell carcinoma. (PubMed id 14995078)^{1, 9} Brown J.J....Liu X. (2003)
1033. Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. (PubMed id 12584563)^{1, 9} Bougeard G....Frebourg T. (2003)
1034. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. (PubMed id 14577584)^{1, 9} Katiyar S....Das B.C. (2003)
1035. Use of the comet-FISH assay to demonstrate repair of the TP53 gene region in two human bladder carcinoma cell lines. (PubMed id 12492368)^{1, 9} McKenna D.J....McKelvey-Martin V.J. (2003)
1036. Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma. (PubMed id 14654549)^{1, 9} Ikeda S....Asahara T. (2003)
1037. MIB-1, p53, bcl-2, and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical carcinomas: correlation with clinical outcome. (PubMed id 11956602)^{1, 9} Graflund M....Karlsson M. (2002)
1038. p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. (PubMed id 12459171)^{1, 9} Bonafe M....Franceschi C. (2002)
1039. Transactivation of repair genes by BRCA1. (PubMed id 12496474)^{1, 9} El-Deiry W.S. (2002)
1040. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. (PubMed id 12209584)^{1, 9} Magrini R....Hanski C. (2002)
1041. The proline form of p53 codon 72 polymorphism is associated with endometriosis. (PubMed id 11779589)^{1, 9} Chang C.C....Lin C.C. (2002)
1042. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. (PubMed id 12496479)^{1, 9} Sood A.K....Klingelhutz A. (2002)
1043. Minor role for BRCA2 (exon11) and p53 (exon 5-9) among Sudanese breast cancer patients. (PubMed id 11883440)^{1, 9} Masri M.A....Ibrahim M.E. (2002)
1044. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. (PubMed id 12496062)^{1, 9} Langerod A....Borresen-Dale A.L. (2002)
1045. Epstein Barr virus associated pediatric nasopharyngeal carcinoma: its correlation with p53 and bcl-2 expression. (PubMed id 11979459)^{1, 9} Preciado M.V....Zubizarreta P. (2002)
1046. P53 immunohistochemical expression: messages in cervical carcinogenesis. (PubMed id 12190289)^{1, 9} Cheah P.L. and Looi L.M. (2002)
1047. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. (PubMed id 11852106)^{1, 9} Choudhuri T....Sa G. (2002)
1048. Distribution of p53 codon 72 polymorphism in Indian primary open angle glaucoma patients. (PubMed id 12368717)^{1, 9} Acharya M....Ray K. (2002)
1049. Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. (PubMed id 11807792)^{1, 9} Nagpal J.K....Das B.R. (2002)
1050. P53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. (PubMed id 12144687)^{1, 9} Pegoraro R.J....Moodley J. (2002)
1051. Discordance of genetic alterations between primary head and neck tumors and corresponding metastases associated with mutational status of the TP53 gene. (PubMed id 11793443)^{1, 9} Tabor M.P....Brakenhoff R.H. (2002)
1052. Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement. (PubMed id 12217802)^{1, 9} Bellido M....Nomdedeu J.F. (2002)
1053. [Relationship between expressions of telomerase genes and apoptosis related genes in mammary ductal atypical hyperplasia] (PubMed id 12452037)^{1, 9} Song M....Song J.Y. (2002)
1054. Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. (PubMed id 12007715)^{1, 9} Kim M.Y....Houh D. (2002)
1055. Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. (PubMed id 11786482)^{1, 9} Chopin V....Le Bourhis X. (2002)
1056. P53 codon 72 polymorphism and susceptibility to development of human papilloma virus-associated cervical cancer in Indian women. (PubMed id 12534455)^{1, 9} Nagpal J.K....Das B.R. (2002)
1057. p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. (PubMed id 12467072)^{1, 9} Li T....Ke Y. (2002)
1058. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. (PubMed id 11458982)^{1, 9} Sayhan N....Dalay N. (2001)
1059. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain. (PubMed id 11245491)^{1, 9} Gu J....Yuan Z.M. (2001)
1060. Nuclear extracellular signal-regulated kinase 2 phosphorylates p53 at Thr55 in response to doxorubicin. (PubMed id 11409876)^{1, 9} Yeh P.Y....Cheng A.L. (2001)
1061. P53 codon 72 polymorphism in bladder cancer--no evidence of association with increased risk or invasiveness. (PubMed id 11828992)^{1, 9} Toruner G.A....Ozcelik T. (2001)
1062. p53 codon 72 polymorphism and human papillomavirus associated skin cancer. (PubMed id 11429426)^{1, 9} O'Connor D.P....Mabruk M.J. (2001)
1063. Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer. (PubMed id 11518545)^{1, 9} Graziano F....Catalano G. (2001)
1064. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. (PubMed id 11746272)^{1, 9} Henner W.D....Beer T.M. (2001)
1065. UV-induced DNA incision and proliferating cell nuclear antigen recruitment to repair sites occur independently of p53-replication protein A interaction in p53 wild type and mutant ovarian carcinoma cells. (PubMed id 11751427)^{1, 9} Riva F....Prosperi E. (2001)
1066. Estrogen receptor protects p53 from deactivation by human double minute-2. (PubMed id 10766163)^{1, 9} Liu G....Brooks S.C. (2000)
1067. p53 codon 72 polymorphism in cervical cancer patients and healthy women from Poland. (PubMed id 11996107)^{1, 9} Dybikowska A....Podhajska A. (2000)
1068. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. (PubMed id 11097231)^{4, 9} Slebos R.J....Taylor J.A. (2000)
1069. Association between INK4a-ARF and p53 mutations in skin carcinomas of xeroderma pigmentosum patients. (PubMed id 11078762)^{4, 9} Soufir N....Basset-Seguin N. (2000)
1070. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. (PubMed id 10487631)^{4, 9} Wang-Gohrke S....Runnebaum I.B. (1999)
1071. Germline mutations of p53 but not p16/CDKN2 or PTEN/MMAC1 tumor suppressor genes predispose to gliomas. The ANOCEF Group. Association des NeuroOncologues d'Expression Francaise. (PubMed id 10589545)^{4, 9} Zhou X.P....Hamelin R. (1999)
1072. Poly(ADP-ribose) binds to specific domains of p53 and alters its DNA binding functions. (PubMed id 9565608)^{1, 9} Malanga M....Althaus F.R. (1998)
1073. Replication error phenotype and p53 gene mutation in lymphomas of mucosa-associated lymphoid tissue. (PubMed id 8579126)^{4, 9} Peng H....Pan L. (1996)
1074. Reduced messenger RNA expression level of p21 CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. (PubMed id 8797864)^{4, 9} Matsushita K....Isono K. (1996)
1075. Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer. (PubMed id 9816336)^{4, 9} Gallo O....Porfirio B. (1996)
1076. Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas. (PubMed id 8107196)^{4, 9} Edwards R.H. and Raab-Traub N. (1994)
1077. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. (PubMed id 8513440)^{1, 9} Casey G....Korc M. (1993)
1078. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. (PubMed id 8385572)^{4, 9} Enomoto T....Nomura T. (1993)
1079. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. (PubMed id 1631137)^{1, 9} Frebourg T....Friend S.H. (1992)
1080. Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. (PubMed id 1349175)^{1, 9} Iavarone A....Israel M.A. (1992)
1081. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. (PubMed id 1319835)^{4, 9} Kikuchi-Yanoshita R....Mori T. (1992)
1082. Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. (PubMed id 1679237)^{1, 9} Metzger A.K....Cogen P.H. (1991)
1083. p53 germline mutations in Li-Fraumeni syndrome. (PubMed id 1683921)^{1, 9} Santibanez-Koref M.F....Harris M. (1991)
1084. Foxp3 expression in p53-dependent DNA damage response s. (PubMed id 20075077)^{1, 9} Jung D.J....Lee W.J. (2010)